Inhibitors of abnormal phosphorylation and TAU protein aggregation

By developing anionic lipid oligosaccharide compounds to simulate heparan sulfate, the problem of abnormal phosphorylation and aggregation of Tau proteins in the prior art is solved, effective treatment of Alzheimer's disease is achieved, and a small molecule is provided Mediator treatment plans have application potential in non-hospital settings.

CN118922429APending Publication Date: 2024-11-08UNIV DE PICARDIE JULES VERNE +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280089714.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-11-29
Filing Date
2022-11-29
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing Alzheimer's disease treatment methods are difficult to effectively prevent the abnormal phosphorylation and aggregation of Tau protein, leading to disease progression, and immunotherapy targeting Tau protein has problems with stability and transmission, and there is a lack of small molecule blocking strategies.

Method used

An anionic lipid oligosaccharide compound was developed to simulate heparan sulfate, which can protect Tau protein from abnormal phosphorylation in vitro and reduce heparin-induced Tau protein aggregation, inhibiting abnormal phosphorylation of Tau through competitive action.

Benefits of technology

These compounds can effectively prevent or slow the progression of Alzheimer's disease, and by inhibiting the abnormal phosphorylation and aggregation of Tau protein, it provides a small-molecular mediated treatment plan with application potential in non-hospital settings.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004956134750000021
    Figure BDA0004956134750000021
  • Figure BDA0004956134750000022
    Figure BDA0004956134750000022
  • Figure BDA0004956134750000051
    Figure BDA0004956134750000051
Patent Text Reader

Abstract

The present disclosure relates to lipid anionic oligosaccharides and their use in medicine, especially in the treatment of conditions associated with abnormal hyperphosphorylation of Tau protein, such as Alzheimer's disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to anionic lipooligosaccharides and their use in medicine, in particular to their use in treating conditions associated with abnormal hyperphosphorylation of Tau protein (such as Alzheimer's disease). Background Art

[0002] Alzheimer's disease (AD) is the most common age-related dementia in the world. According to the World Health Organization (WHO), it is the cause of 60-70% of dementia cases. More than 50 million people are affected by AD worldwide, with 10 million new cases recorded each year. According to WHO forecasts, the total number of people with dementia is expected to reach 82 million in 2030 and 152 million by 2050.

[0003] This disease not only affects the health and morale of patients and their families, but also imposes a significant economic burden on society.

[0004] AD is characterized by a progressive loss of cognitive abilities associated with severe neuronal degeneration. Histopathologically, AD is characterized by two types of brain lesions: on the one hand, senile plaques (or amyloid), which are extracellular aggregates of β-amyloid peptide (Aβ), and on the other hand, neurofibrillary tangles (NFTs), which correspond to the intracellular accumulation of abnormally phosphorylated Tau protein (MAPT, microtubule-associated protein Tau) (P-Tau).

[0005] Despite significant academic and industrial research efforts over the past 20 years, no treatment has been developed that effectively and sustainably halts the progression of neurodegenerative diseases.

[0006] Since it is widely accepted that amyloid plaques and NFTs composed of P-Tau are involved in functional changes in neurons, most treatments developed have specifically targeted the gradual accumulation of β-amyloid and, more recently, Tau. However, the failure of treatments targeting different stages of the amyloid J3 (AJ3) cascade suggests that AJ3 accumulation is not the central pathological process of the disease, but rather the abnormal phosphorylation and aggregation of Tau, which should be targeted to combat the disease.

[0007] Tau protein is a member of the microtubule-associated protein (MAP protein) family. In humans, one of the main functions of Tau protein is to stabilize the cytoskeleton of neurons by interacting with tubulin, thereby allowing axon stability. In AD, the abnormal phosphorylation-induced protein of Tau separates from the cytoskeleton, and soluble Tau protein aggregates to eventually form the NFT feature of AD. It has been shown that there is a direct correlation between the clinical evolution of the disease and the accumulation of abnormally phosphorylated and aggregated Tau proteins in the form of neurofibrillary tangles (NFTs) in the brain.

[0008] Several kinases are able to phosphorylate Tau (cdK5, NCLK, GSK-3β, and MARK), but this occurs in a non-specific manner, as several other proteins are also their substrates. Therefore, inhibiting one of the kinases will not prevent the action of the others. In line with this, although a great deal of work has been done on kinase inhibitors as well as phosphatases (also non-specific) that are considered as therapeutic targets, to date, no positive results have been obtained to prevent or slow the disease by inhibiting the activity of these enzymes alone, whether by kinase inhibitors, phosphatase activators, or NFT dissociators.

[0009] So far, the treatment targeting Tau protein under development is mainly based on immunotherapy at the extracellular level. The antibodies used are directed against Tau fragments, aiming to reduce the extracellular forms of Tau protein that are more or less aggregated. However, these extracellular forms are produced in cells by phosphorylation of Tau protein; after extracellular secretion, these aggregated forms of Tau seem to help spread the condition in brain tissue. At present, immunotherapy targeting Tau protein remains the main hope in this field, despite all the inherent difficulties of immunotherapy, especially the inaccessibility of the process involving intracellular antibodies to prevent abnormal phosphorylation and aggregation of Tau protein, the stability of these products, the production of anti-antibodies, and the need for treatment in a hospital setting (Schroeder SK et al., Neuroimmune Pharmacol. 2016, 11 (1): 9-25.). Therefore, it is generally believed that the best strategy will be a strategy involving small and stable molecules that can block the hyperphosphorylation and aggregation of Tau and can be applied to patients by conventional protocols in a non-hospital setting.

[0010] Therefore, there is still a need to provide compounds that are able to prevent or slow the progression of pathologies associated with Tau hyperphosphorylation, in particular Alzheimer's disease. Summary of the invention

[0011] The present invention relates to a compound of the following formula (I) for use in medicine (particularly for the treatment of Tauopathy):

[0012]

[0013] in:

[0014] L is a -C(=O)NH-, -C(=O)O- or -C(=O)S- group;

[0015] R1 is a linear or branched, saturated or unsaturated hydrocarbon chain containing 15, 16, 17 or 18 carbon atoms, optionally substituted at the terminal position with a group selected from -OH, -OR, -NH2, -NHR, -NRR', -COOH, -COOR, -CONHR, -CONRR' and -SR, wherein R and R' independently represent an alkyl group containing from one to six carbon atoms;

[0016] R4 is a group of formula (IIa) or (IIb):

[0017]

[0018] in:

[0019] R9 and R 10 independently of one another are a hydrogen atom or a sulfonic acid group in ionized form;

[0020] R 12 is an alkyl radical containing from one to six carbon atoms;

[0021] R 11 Is -CH2-OR5 or -CONHR 13 Group, in which:

[0022] R5 is a hydrogen atom or a sulfonic acid group in ionized form;

[0023] R 13 is an alkyl radical containing from one to six carbon atoms;

[0024] R2, R3, R6, R7 and R8 are independently of one another a hydrogen atom or a sulfonic acid group in ionized form; and

[0025] Among them, R2, R3, R5, R6, R7, R8, R9 and R 10 At least one of the groups, preferably R2, R3, R5, R6, R7, R8, R9 and R 10 At least two of the groups are sulfonic acid groups in ionized form.

[0026] The present invention also relates to pharmaceutical compositions comprising at least one compound of formula (I) as described herein and one or more pharmaceutically acceptable excipients, and the use of said pharmaceutical compositions in the treatment of Tauopathy.

[0027] Other aspects of the invention are described below and in the claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 : Schematic representation of the action of heparan sulfate (HS).

[0029] Figure 2 : Western blot showed that Tau phosphorylation mediated by GSK3β at sites characteristic of Alzheimer's disease was dependent on the presence of heparin in the reaction mixture (Sepulveda-Diaz JE et al. Brain. 2015 May;138(Pt 5):1339-54).

[0030] Figure 3 : Western blot showed that after 3 h of in vitro reaction, the presence of disulfated C16 maltobionamide (Mal16diS) inhibited the abnormal phosphorylation of Tau (P-Tau) revealed by Alzheimer's disease characteristic antibodies (AT270 and Ser199 / 202).

[0031] Figure 4 : Western blot showed that after 3 hours of reaction, the presence of disulfated C18 maltobisamide (Mal18diS) inhibited the abnormal phosphorylation of Tau (P-Tau) revealed by Alzheimer's disease characteristic antibodies (AT270, pSer199 / 202).

[0032] Figure 5 : Western blot comparing the P-Tau inducing ability of compounds derived from disulfated maltobiose amide (revealed by AT270 antibody) as a function of the length of the hydrocarbon chain (R1) (Mal14diS to Mal20diS corresponding to chains of 14 to 20 carbons) and heparin ("Hep") after 3 h of reaction.

[0033] Figure 6 : After 3 h of reaction, the abnormal phosphorylation of Tau (P-Tau) of different derivatives was evaluated by Western blotting according to their disaccharide (monosulfated or disulfated) and the length of the hydrocarbon chain (14 to 20 carbons), as revealed by antibodies characteristic of Alzheimer's disease (AT270 and Ser199 / 202).

[0034] Figure 7 : Western blot comparing the ability of disulfated maltobiose amide (Mal16diS, Mal18diS) to protect Tau protein from heparin-induced aberrant phosphorylation, revealed by AT270 antibody, compared to the oxidized form with 16 carbons (Mal16diOx) and the oxidized form with 18 carbons (Mal18diOx).

[0035] Figure 8 : Western blots compared the effect of disaccharide sulfation (monoS and triS) on 16- or 18-carbon maltobiose amide to effectively protect Tau from heparin-induced aberrant phosphorylation, revealed by the AT270 antibody, using 2 batches of compounds (for Mal16, Mal16monoS, Mal16triS, for Mal18, Mal18monoS and Mal18triS).

[0036] Fig. 9 : Western blot comparing the ability of a persulfated 16-carbon maltobiose amide molecule (Mal16perS) to its potent disulfated homologues (Mal16diS, Mal18diS) to effectively protect Tau from aberrant heparin-induced phosphorylation, revealed by the AT270 antibody.

[0037] Fig.10 : Tau aggregation was monitored by incorporation of Thioflavin-T, a fluorescent compound that is incorporated into aggregates, in the presence of heparin (Tau:Hep mass ratio of 2:1 or 4:1) or 16-carbon disulfated maltodisylamide (Mal16diS) (Tau:oligomer mass ratio of 4:1). n represents the number of repeats.

[0038] Fig.11 : Cytotoxicity of 16-carbon disulfated maltobiosylamide (Mal16diS) at concentrations of 0.1, 1, 10, or 100 μg / mL.

[0039] Fig.12 : Cytotoxicity of 18-carbon disulfated maltobiosylamide (Mal18diS) at concentrations of 0.1, 1, 1, 10, or 100 μg / mL.

[0040] Fig.13 : 16-carbon disulfated maltobiose amide compound (Mal16diS) at a concentration of 1, 10 or 100 μg / mL protected against Tau phosphorylation in cells. t-test: *p<0.05, ***p<0.001; number of replicates ≥5.

[0041] Fig.14 : 18-C disulfated maltobiose amide compound (Mal18diS) at a concentration of 1, 10 or 100 μg / ml protected against Tau phosphorylation in cells. t-test: *p<0.05, ***p<0.001; number of replicates ≥5.

[0042] Fig.15: Effect of Cell16diS on P-Tau in the SHSY5Y model of induced tauopathy. t-test was not significant; number of replicates ≥3.

[0043] Fig.16 : Effect of Lac16diS on P-Tau in SHSY5Y model of induced tauopathy. t-test: *p<0.05; number of replicates ≥3.

[0044] Fig.17 : In the cortical cells of the rTg4510 mouse model, 16-carbon disulfated maltobiose amide compound (Mal16diS) at a concentration of 0.1 or 1 μg / mL showed a moderate reduction in Tau phosphorylation (culture day 14). t-test: **p<0.01, ***p<0.001; number of replicates = 4.

[0045] Fig.18 : In the cortical cells of the rTg4510 mouse model, 16-carbon disulfated maltobiose amide compound (Mal16diS) at a concentration of 0.1 or 1 μg / mL showed a severe reduction in Tau phosphorylation (culture day 18). t-test: not significant; number of replicates = 4. DETAILED DESCRIPTION

[0046] It has been found that anionic lipooligosaccharides (compounds of formula (I)) as described below are able to protect Tau protein from abnormal hyperphosphorylation, do not induce abnormal hyperphosphorylation of Tau itself, and are able to reduce heparin-induced Tau protein aggregation, which is the prototype of the hypersulfated heparan sulfate present in Alzheimer's disease (Sepulveda-Diaz Je et al., Brain. 2015 May; 138(Pt 5): 1339-54).

[0047] Therefore, the anionic lipid oligosaccharides of the present invention are shown to be useful for treating conditions associated with abnormal Tau protein hyperphosphorylation, and in particular for treating Alzheimer's disease. It can be shown that these compounds are able to prevent or slow the progression of the disease.

[0048] These anionic lipooligosaccharides mimic some of the characteristics of heparan sulfate. The biologist team of Gly-CRRET (Holmes BB et al., Proc Natl Acad Sci USA. 2013 Aug 13;110(33); Sepulveda-Diaz JE et al., Brain. 2015 May;138(Pt 5):1339-54; A et al., FEBS Lett. 2018 Dec;592(23):3806-3818) and other teams around the world (Goedert M et al., Nature. 1996 Oct 10;383(6600):550-3; Zhao J et al., Biophys J. 2017 Mar 14;112(5):921-932) have shown that heparan sulfate is critical for the development and progression of the disease:

[0049]

[0050] Heparan sulfate is a copolymer of uronic acid (D-glucuronic acid or L-iduronic acid) and D-glucosamine, which may be N-acetylated and contain sulfation sites.

[0051] In particular, the Gly-Cret laboratory showed that conformational changes in Tau that allow its abnormal hyperphosphorylation and its aggregation in neurons are the result of the protein's interaction with heparan sulfate (HS) chains internalized in neurons of subjects with the disease. By acting as a molecular chaperone, HS allows the Tau protein to acquire a conformation that is favorable for kinase attack, leading to abnormal hyperphosphorylation and aggregation of the protein ( Figure 1 ).

[0052] Furthermore, studies by Gly-CRRET and other groups have shown that HS are receptors for cell surface Tau aggregates (proteopathic seeds), which are centrally involved in the transfer of Tau fibrils from diseased cells to healthy cells, a process known as spreading (Holmes BB et al., Proc Natl Acad Sci US A. 2013 Aug 13; 110(33)). Tau spreading is currently believed to be responsible for the spread of the disease between cells and between different regions of the brain. The presence of HS in Tau inclusions in vivo, and their ability to trigger abnormal Tau phosphorylation, aggregation, and spreading, suggest that these polysaccharides play a central role in the establishment and progression of neurodegenerative processes.

[0053] Lipid anionic oligosaccharides

[0054] Compounds according to the invention or compounds useful in the context of the present invention are compounds of the following formula (I):

[0055]

[0056] in:

[0057] L is a -C(=O)NH-, -C(=O)O- or -C(=O)S- group;

[0058] R1 is a linear or branched, saturated or unsaturated hydrocarbon chain containing 15, 16, 17 or 18 carbon atoms, optionally substituted at the terminal position with a group selected from -OH, -OR, -NH2, -NHR, -NRR', -COOH, -COOR, -CONHR, -CONRR' and -SR, wherein R and R' independently represent an alkyl group containing from one to six carbon atoms;

[0059] R4 is a group of formula (IIa) or (IIb):

[0060]

[0061] in:

[0062] R9 and R 10 independently of one another are a hydrogen atom or a sulfonic acid group in ionized form;

[0063] R 12 is an alkyl radical containing from one to six carbon atoms;

[0064] R 11 Is -CH2-OR5 or -CONHR 13 Group, in which:

[0065] R5 is a hydrogen atom or a sulfonic acid group in ionized form;

[0066] R 13 is an alkyl radical containing from one to six carbon atoms;

[0067] R2, R3, R6, R7 and R8 are independently of one another a hydrogen atom or a sulfonic acid group in ionized form; and

[0068] Among them, R2, R3, R5, R6, R7, R8, R9 and R 10 At least one of the groups, preferably R2, R3, R5, R6, R7, R8, R9 and R 10 At least two of the groups are sulfonic acid groups in ionized form.

[0069] More specifically, compounds according to the invention or compounds useful in the context of the present invention are compounds of the following formula (I):

[0070]

[0071] in:

[0072] L is a -C(=O)NH-, -C(=O)O- or -C(=O)S- group;

[0073] R1 is a linear or branched, saturated or unsaturated hydrocarbon chain containing 15, 16, 17 or 18 carbon atoms, optionally substituted at the terminal position with a group selected from -OH, -OR, -NH2, -NHR, -NRR', -COOH, -COOR, -CONHR, -CONRR' and -SR, wherein R and R' independently represent an alkyl group containing from one to six carbon atoms;

[0074] R2 is a hydrogen atom or a sulfonic acid group in ionized form;

[0075] R3 is a hydrogen atom or a sulfonic acid group in ionized form;

[0076] R4 is a group of formula (IIa):

[0077]

[0078] in:

[0079] R9 and R 10 independently of one another are a hydrogen atom or a sulfonic acid group in ionized form;

[0080] R5, R7 and R8 are independently a hydrogen atom or a sulfonic acid group in ionized form;

[0081] R6 is a hydrogen atom or a sulfonic acid group in ionized form; and

[0082] Among them, R2, R3, R5, R6, R7, R8, R9 and R 10 At least one of the groups, preferably R2, R3, R6, R7, R8, R9 and R 10 At least two of the groups are sulfonic acid groups in ionized form.

[0083] The expression "sulfonic acid group in ionized form" means a -SO3- group.

[0084] The compound of formula (I) is preferably in the form of a salt, in particular in the form of a sodium salt. Thus, the sulfonic acid group in ionized form is preferably a sodium sulfonate group (-SO3Na).

[0085] In some embodiments, the compound of formula (I) has two, three, four, five, six, seven or eight sulfonic acid groups in ionized form. 10 Two, three, four, five, six, seven or all of the groups may be sulfonic acid groups in ionized form. However, since highly charged compounds may cause toxicity, compounds containing two or three ionized sulfonic acid groups may be preferred.

[0086] In some embodiments, L is a -C(=O)NH- group.

[0087] In some embodiments, compounds of the invention or compounds useful in the context of the invention have the following formula (Ia):

[0088]

[0089] wherein R1 to R8 are as described above, and wherein R2, R3, R5, R6, R7, R8, R9 and R 10 At least one of the groups, preferably R2, R3, R5, R6, R7, R8, R9 and R 10 At least two of the groups are sulfonic acid groups in ionized form.

[0090] In some embodiments, compounds of the invention or compounds useful in the context of the invention have the following formula (Ib):

[0091]

[0092] Where R1 to R3 and R5 to R 10 As described above or as described below, and wherein R2, R3, R5, R6, R7, R8, R9 and R 10 At least one of the groups, preferably R2, R3, R5, R6, R7, R8, R9 and R 10 At least two of the groups are sulfonic acid groups in ionized form.

[0093] In formulae (I), (Ia) and (Ib), R1 is preferably a saturated linear hydrocarbon chain containing 15, 16, 17 or 18 carbon atoms, preferably 16 and 18 carbon atoms.

[0094] In formula (I), (Ia) and (Ib), R2, R3 and R 10 Preferred is a hydrogen atom.

[0095] In the formulae (I), (Ia) and (Ib), R5 is preferably a sulfonic acid group in ionized form, and R6, R7 and R8 are hydrogen atoms.

[0096] In the formulae (I), (Ia) and (Ib), R9 is preferably a sulfonic acid group in ionized form.

[0097] In some embodiments, compounds of the invention or compounds useful in the context of the invention have the following formula (Ib):

[0098]

[0099] in:

[0100] R1 is a saturated straight hydrocarbon chain containing 15, 16, 17 or 18 carbon atoms, preferably 16 or 18 carbon atoms;

[0101] R2, R3, R6, R7, R8 and R 10 is a hydrogen atom, or R2, R3, R6, R7, R8 and R 10 Only one of the groups is a sulfonic acid group in ionized form and the others are hydrogen atoms; and

[0102] R5 and R9 are sulfonic acid groups in ionized form.

[0103] In some embodiments, compounds of the invention or compounds useful in the context of the invention have the following formula (Ib):

[0104]

[0105] in:

[0106] R1 is a saturated straight hydrocarbon chain containing 15, 16, 17 or 18 carbon atoms, preferably 16 or 18 carbon atoms;

[0107] R2, R3, R6, R7, R8 and R 10 is a hydrogen atom; and

[0108] R5 and R9 are sulfonic acid groups in ionized form.

[0109] In some embodiments, compounds of the invention or compounds useful in the context of the invention have the following structure (Ic):

[0110]

[0111] Where R1 to R3 and R5 to R 10 As mentioned above.

[0112] In some embodiments, compounds of the invention or compounds useful in the context of the invention have the following structure (Id):

[0113]

[0114] Among them, R1, R2, R3 and R6 to R8 and R 10 As mentioned above.

[0115] In some embodiments, compounds of the invention or compounds useful in the context of the invention have the following structure (Ie):

[0116]

[0117] Where R1 to R3 and R5 to R 10 As mentioned above.

[0118] In some embodiments, compounds of the invention or compounds useful in the context of the invention have the following structure (If):

[0119]

[0120] Among them, R1, R2, R3 and R6 to R8 and R 10 As mentioned above.

[0121] In some embodiments, compounds of the invention or compounds useful in the context of the invention have the following structure (Ig):

[0122]

[0123] Where R1 to R3 and R5 to R 10 As mentioned above.

[0124] In some embodiments, compounds of the invention or compounds useful in the context of the invention have the following structure (Ih):

[0125]

[0126] Among them, R1, R2, R3 and R6 to R8 and R 10 As mentioned above.

[0127] In some embodiments, the compound of the present invention is a compound of formula (I), with the proviso that the compound is not sodium hexadecyl D-lactobiosamide (2,5) sulfate, i.e., sodium hexadecyl D-lactobiosamide disulfate, sodium hexadecyl D-lactobiosamide trisulfate, and mixtures thereof.

[0128] Non-limiting examples of compounds of formula (I) include compounds of formula (I) shown in Table 1 in the "Examples" section.

[0129] Process for preparing compounds of formula (I)

[0130] The schemes and procedures described below illustrate synthetic routes to compounds of formula (I) and should not be considered limiting.

[0131] The compound of formula (I) can be prepared in three steps from disaccharides (such as maltose, cellobiose or lactose). The method comprises the following steps:

[0132] (Step 1) oxidizing the anomeric position of the disaccharide;

[0133] (Step 2) synthesizing a methyl ester by mechanical synthesis under solvent-free conditions and performing aminolysis to graft a hydrocarbon chain (R1);

[0134] (Step 3) The primary hydroxyl groups are selectively sulfated or oversulfated.

[0135] The following reaction diagram (schematic Figure 1 ) describes such a method, wherein the disaccharide is maltose. It should be understood that maltose can be replaced by any suitable disaccharide.

[0136]

[0137] Hint Figure 1 : Synthetic route of the compound of formula (I) from maltose

[0138] Step 1 :

[0139] The anomeric position of the disaccharide can be oxidized according to well-known methods, for example, by method A described in ACS Sustainable Chemistry & Engineering 2016, 4(4), 2432-2438.

[0140] Alternatively, sodium maltobionate can be prepared by photocatalysis (Omri M. et al., ACSCatalysis 2018) with the same conversion: >99%, selectivity: >95% (estimated by NMR).

[0141] Step 2: One-pot synthesis of N-alkyl D-maltobiose amide derivatives

[0142] It is produced by a solvent-free mechanosynthesis process. Potassium gluconate is ground in a ball mill in the presence of a supported acid catalyst (H2SO4 / SiO2) and methanol (the exact amount required to methylate the carboxylic acid formed), and then in a second step, the alkylamine is added after the gluconate has been completely converted to the ester. For both steps combined, quantitative conversions of step 2 that can be obtained are typically greater than 85%.

[0143] Step 3 : According to the protocol of the literature, the sulfation step was carried out in a pyridine medium in the presence of a sulfating agent SO3-pyridine (Tetrahedron. 2010 April 17; 66(16): 2907-2918).

[0144] Hereinafter, the expression "compound of formula (I)" refers to the compound of formula (I) as described above, including the compounds described in the "Examples" section. The expression "compound of formula (I)" refers to a single compound of formula (I), or a mixture of two or more compounds of formula (I).

[0145] Therapeutic applications

[0146] It has been shown that compounds of formula (I) effectively protect Tau protein from abnormal heparin-induced hyperphosphorylation, weakly induce Tau protein phosphorylation, and reduce heparin-induced Tau protein aggregation. Therefore, compounds of formula (I) have been shown to be useful medically, particularly in the treatment of conditions associated with abnormal hyperphosphorylation or phosphorylation of Tau protein (Tauopathy), and particularly in the treatment of Alzheimer's disease. The compounds of formula (I) will act by inhibiting abnormal phosphorylation of Tau before the aggregation process and the proliferation of aggregates, not by inhibiting kinases, but by protecting Tau from its attack.

[0147] The present invention therefore relates to compounds of formula (I) for use in medicine or formulated in a different manner as medicaments.

[0148] More specifically, the present invention relates to compounds of formula (I) for use in treating conditions associated with abnormal hyperphosphorylation or phosphorylation of Tau protein (commonly referred to as "Tauopathies"). Non-limiting examples of Tauopathies include Alzheimer's disease, frontotemporal dementia with parkinsonism on chromosome 17 (DFTP17), Pick's disease, corticobasal degeneration, and progressive supranuclear palsy (PSP).

[0149] Thus, in a specific embodiment, the invention relates to a compound of formula (I) for use in the treatment of Alzheimer's disease, frontotemporal dementia with parkinsonism on chromosome 17 (DFTP17), Pick's disease, corticobasal degeneration or progressive supranuclear palsy. In a specific embodiment, the invention relates to a compound of formula (I) for use in the treatment of Alzheimer's disease.

[0150] The present invention also relates to the use of the compound of formula (I) in the preparation of a medicament, wherein the medicament can be used to treat a condition associated with abnormal hyperphosphorylation or phosphorylation of Tau protein (Tauopathy), in particular, can be used to treat Alzheimer's disease.

[0151] Pharmaceutical composition

[0152] The present invention also relates to a pharmaceutical composition, in particular a medicament, comprising a compound of formula (I) and one or more excipients, in particular one or more pharmaceutically acceptable excipients, and also to its use in the above-mentioned therapeutic applications.

[0153] The term "pharmaceutically acceptable" refers to something that is known to be non-toxic and can be used in medicine. Pharmaceutically acceptable excipients are well known in the medical literature.

[0154] The excipient is selected according to the desired pharmaceutical form and method of administration. Such excipients are well known to the skilled person.

[0155] The pharmaceutical composition according to the invention may be administered parenterally, such as intravenously or intradermally, or topically, orally or nasally.

[0156] The form that can be administered parenterally includes aqueous suspensions, isotonic saline solutions or sterile injection solutions, which may contain pharmacologically compatible dispersants and / or wetting agents. The form that can be administered orally includes tablets (which may be dispersible tablets, orodispersible tablets, effervescent tablets or soluble tablets), soft capsules or hard capsules, powders, granules and oral solutions and suspensions. The form that can be administered nasally includes aerosols. The form that can be applied topically includes patches, gels, creams, ointments, lotions, sprays and eye drops. Preferably, the compound or composition of the present invention is administered orally or parenterally (especially intravenously).

[0157] The present invention also relates to a method for treating the above-mentioned conditions, which comprises administering to a subject in need thereof an effective dose of a compound of formula (I), or administering a pharmaceutical composition comprising a compound of formula (I) and one or more pharmaceutically acceptable excipients.

[0158] The effective dosage of the compounds of formula (I) varies, depending on many parameters, such as the chosen route of administration, body weight, age, sex, the progress of the condition to be treated and the sensitivity of the individual to be treated.

[0159] The following examples are given for illustrative purposes only and should in no way be construed as limiting the present invention.

[0160] Example

[0161] I. Tested Compounds

[0162] The compounds tested are shown in Table 1 below.

[0163] Table 1 : Tested compounds

[0164]

[0165]

[0166]

[0167] II. Synthesis of Tested Compounds

[0168] II-1. Chemical Materials and Methods

[0169] a) Reagents and solvents

[0170] Reagents used were from Merck, Acros or Alfa Aesar and were used without purification. Solvents were purchased in anhydrous form or distilled under an inert atmosphere and treated with 3 or 4 angstrom molecular sieves.

[0171] b) Ball milling

[0172] The reactions were performed in a Fritsch Pulverisette Premium 7 (P7PL) planetary mill equipped with two 20 mL bowls, each containing 80 zirconium oxide (ZrO2) balls with a diameter of 5 mm.

[0173] c) Chromatography

[0174] Thin layer chromatography (TLC) Thin layer chromatography was performed on silica plates, using Xtra SIL G / UV 254 Aluminum support, for reverse phase use RP-18 / UV 254 Aluminum support. The techniques used to reveal the product after elution are: 4% H2SO4 / EtOH or cerium(IV) molybdate: (NH4)4Ce(SO4).2H2O, (NH4)6Mo7O 24 .4H2O, H2SO4, H2O (2.1g / 5.3g / 12mL / 188mL) and then heated.

[0175] Automated flash chromatography . Use Grace Fast Device ( The iES Flash System is used for automated rapid purification. Separation is performed using commercially available pre-packed normal phase or C18 silica columns (4 g, 12 g, 24 g, 40 g, 80 g). Purification can be performed in normal phase as well as in reverse phase. The mass of the crude product corresponds to a maximum of 10% of silica in the pre-packed column. The device is equipped with a light diffusion detector (DEDL) and a UV detector with two configurable wavelengths.

[0176] d) Characterization of compounds

[0177] Specific rotation

[0178] The specific rotation is measured at a temperature of 20° C. using a Perkin-Elmer 343 polarimeter which emits polarized light at λ=549 nm (sodium D line). The concentration c is expressed in grams per 100 mL of solvent.

[0179] Low-resolution mass spectrometry .

[0180] Low-resolution mass spectrometry was performed on a single quadrupole device (Micromass-Waters ZQ) with an electrospray ionization source (Z-spray). The device allows analysis in positive or negative ionization mode. The capillary voltage was 3.5 kV, and the cone voltage varied from 20 V to 120 V. The source temperature and desolvation temperature were 80°C and 150°C, respectively. The desolvation and nebulization gas was nitrogen.

[0181] High-resolution mass spectrometry .

[0182] High-resolution mass spectrometry (HRMS) analysis was performed on a hybrid quadrupole time-of-flight mass spectrometer (Micromass-Waters Q-TOF Ultima Global) equipped with an electrospray ionization source. The source temperature and desolvation temperature were 80°C and 120°C, respectively. The gas used for nebulization and desolvation was nitrogen with flow rates of 20 and 500 L / h, respectively. The capillary voltage was 3.5 kV, and the cone voltage varied from 100 V to 250 V. Before any accurate mass measurement, calibration was performed with orthophosphoric acid. Since the accuracy of the accurate mass measurement of Q-TOF is less than 5 ppm, the elemental composition of the molecule can be obtained.

[0183] NMR spectroscopy. Generated on a Bruker Advance 400 or 600 MHz spectrometer 1 H NMR and 13 CNMR spectra. Recorded at 400MHz or 600MHz 1 H NMR spectra and recorded at 101 MHz or 150 MHz 13 C NMR spectra. All experiments were performed at temperatures close to 25°C in deuterated solvents (which also served as references). Chemical shifts are in ppm and coupling constants are in Hertz. NMR spectra were processed using MestReNova.

[0184] Carbon number :

[0185]

[0186] II-2 Synthesis of Maltodiose Amide Sulfate

[0187] Unless otherwise stated, maltobiose amide sulfate (including compounds of formula (I)) was prepared according to Scheme (1) in the specification.

[0188] II.2a). Procedure for the synthesis of potassium gluconate

[0189] A 5% aqueous solution of disaccharide (250 mg of disaccharide in 5 mL of MilliQ water) was placed in a 10 mL CEM microwave tube, and then 2 equivalents of K2CO3 and 2.5 mg of Au / Al2O3 catalyst were added, which was prepared according to the protocol described in ACS SustainableChem.Eng., 2016, 4, 2432-2438, and the mixture was sonicated to homogenize it. Then 1.8 equivalents of a 30% aqueous solution of H2O2 was added, and the mixture was placed in a CEM Discover microwave and irradiated at 60°C using the Dynamic program for 20 minutes. The catalyst was then filtered through 0.25 μm PVDF or removed by centrifugation. The filtrate was then freeze-dried and passed through 1 The crude reaction was analyzed by H NMR to monitor the overall conversion of aldose to aldehyde salt. 1 g of disaccharide can be reacted in a 35 mL tube with a reaction time of 50 to 70 minutes, depending on the disaccharide.

[0190] Potassium D-maltodiose (Mal)

[0191]

[0192] Quantitative yield

[0193] Appearance: white solid

[0194] Molecular formula: C 12 H 21 KO 12

[0195] MM:396.39 g.mol -1

[0196] ESI-MS:[MK] - m / z 357Da

[0197] 1H NMR (400MHz, D2O): δ5.20(d,J=3.9Hz,1H,H-1'),4.17(dd,J=6.2,2.6Hz,1H,H-3),4.13( d,J=2.7Hz,1H,H-2),4.03(dt,J=7.7,3.7Hz,1H,H-5),3.98–3.89(m,2H,H-5',H-4),3.8 9–3.80(m,3H,1H-6'a,H-6'b,H-6a),3.77(dd,J=9.2,9.9Hz,1H,H-3'),3.71(dd,1H,J=1 1.9, 7.8Hz, H-6b), 3.59 (dd, J=9.9, 3.8Hz, 1H, H-2'), 3.47 (dd, J=9.1, 10.1Hz, 1H, H-4').

[0198] 13 C NMR(101MHz,D2O): δ178.2(C-1),100.4(C-1'),82.4(C-4),73.0(C-3'),72.6(C-2),7 2.5(C-3),72.4(C-5),72.3(C-5'),71.8(C-2'),69.3(C-4'),62.1(C-6),60.4(C-6').

[0199] D-Cellobionate Potassium (Cell)

[0200]

[0201] Quantitative yield

[0202] Appearance: white solid

[0203] Molecular formula: C 12 H 21 KO 12

[0204] MM:396.39 g.mol -1

[0205] ESI-MS:[MK] - m / z 357Da

[0206] 1H NMR (400MHz, D2O): δ4.63 (d, J=7.9Hz, 1H, H-1'), 4.16 (d, J=3.0Hz, 1H, H-2), 4.09 (dd, J= 5.4,3.0Hz,1H,H-3),4.05–3.94(m,2H,H-4,H-5),3.91(dd,J=12.4,2.1Hz,1H,H-6'a),3. 85(dd,J=12.0,3.1Hz,1H,H-6a),3.78–3.71(m,2H,H-6b,H-6'b),3.52(t,J=9.0Hz,1H,H- 3'), 3.49–3.44 (m, 1H, H-5'), 3.44–3.38 (m, 1H, H-4'), 3.35 (dd, J = 9.4, 7.9Hz, 1H, H-2').

[0207] 13 C NMR(101MHz,D2O): δ178.4(C-1),103.0(C-1'),81.8(C-4),76.0(C-5'),75.6(C-3'), 73.4(C-2'),72.4(C-2),71.8(C-5),71.6(C-3),69.5(C-4'),61.9(C-6),60.6(C-6').

[0208] Potassium D-lactobiose (Lac)

[0209]

[0210] Quantitative yield

[0211] Appearance: white solid

[0212] Molecular formula: C 12 H 21 KO 12

[0213] MM:396.39 g.mol -1

[0214] ESI-MS:[MK] - m / z 357Da

[0215] 1H NMR (400MHz, D2O): δ4.59 (d, J=7.8Hz, 1H, H-1'), 4.20 (d, J=2.9Hz, 1H, H-2), 4.1 3(dd,J=5.3,2.9Hz,1H,H-3),4.06–3.97(m,2H,H-4,H-5),3.94(d,J=3.4Hz,1H, H-4'),3.88(dd,J=12.0,3.1Hz,1H,H-6a),3.84–3.72(m,4H,H-6'a,H-6b,H-6'b ,H-5'),3.70(dd,J=10.0,3.4Hz,1H,H-3'),3.59(dd,J=10.0,7.8Hz,1H,H-2').

[0216] 13 C NMR(101MHz,D2O): δ178.5(C-1),103.5(C-1'),81.7(C-4),75.3(C-5'),72.6(C-3'), 72.5(C-2),71.8(C-5),71.6(C-3),71.1(C-2'),68.7(C-4'),61.9(C-6),61.1(C-6').

[0217] II.2b). Scheme for the synthesis of N-alkyl-D-glubiocinamides via D-glubiocin methyl ester One gram of crude reactive potassium glubiocinate and 1.1 equivalents (about 1 g) of sulfuric acid (H2SO4 / SiO2) supported on commercial 22% silica are placed in a 20 mL zirconium oxide bowl equipped with 80 zirconium oxide (ZrO2) balls with a diameter of 5 mm. One milliliter of methanol is added and the mixture is ground in a P7PL at 500 rpm for 8 cycles of 5 min each. The reaction is then monitored by normal phase thin layer chromatography (TLC) (eluent: ethyl acetate / methanol / water 7 / 2 / 1). The amine (1.5 equivalents) is then added to the reaction medium in the bowl, followed by 2 mL of methanol. The grinding is continued at 500 rpm for 12×5 min. The reaction is again monitored by TLC, with the same eluent. After the reaction is complete, the reaction medium is dried at room temperature. The reground powder was then mixed with unground silica and purified by flash chromatography using the same eluent as used for the monitoring reaction. Fractions containing the glubiocinamide were concentrated in a rotary evaporator and then freeze-dried.

[0218] N-Tetradecyl-D-maltobiose amide (Mal14)

[0219]

[0220] Yield: 93%

[0221] Appearance: white solid

[0222] Molecular formula: C 26 H 51 NO 11

[0223] MM:553.68g.mol -1

[0224] 1 H NMR (400MHz, pyridine-d5): δ8.23(t,1H,J=6.0Hz,NH),5.76(d,1H,J=3.9Hz,H-1'),5.25(dd,1H,J=2.0Hz,J=5.3H z,H-3),5.12(d,1H,J=1.8Hz,H-2),4.76(t,1H,J=5.0Hz,H-4),4.74–4.67(m,2H,H-5,H-5'),4.60(t,1H,J= 9.2Hz,H-3'),4.54(dd,1H,J=1.9Hz,J=11.5Hz,H-6'a),4.40(dd,1H,J=4.7Hz,J=11.3Hz,H-6a),4.37–4.28 (m,2H,H-6b,H-6'b),4.19(dd,1H,J=3.9Hz,J=9.5Hz,H-2'),4.15(t,1H,J=9.5Hz,H-4'),3.55–3.40(m,2H,C H 2-NH), 1.54(p, 2H, J = 7.2 Hz, C H 2-CH2-NH), 1.33–1.12 (m, 22H, CH2 alkyl chain), 0.88 (t, 3H, J=6.6Hz, CH3)

[0225] 13 C NMR (101 MHz, pyridine-d5): δ 174.0 (C-1), 103.4 (C-1'), 85.5 (C-4), 75.9 (C-3'), 75.6 (C-5"), 74.8 (C-5), 74.4 (C-2'), 74.3 (C-2), 74.1 (C-3), 72.4 (C-4'), 64.8 (C-6), 63.1 (C-6'), 39.9 ( C H2-NH), 32.6–23.4 (CH2 alkyl chain), 14.8 (CH3).

[0226] N-hexadecyl-D-maltobiosylamide (Mal16)

[0227]

[0228] Yield: 71%%

[0229] Appearance: white solid

[0230] Molecular formula: C 28 H 55 NO 11

[0231] MM:581.74g.mol -1

[0232] Rf: 0.72 (EtOAc / MeOH / H2O: 7 / 2 / 1)

[0233] [α] D 20 :+71.4°(MeOH,c=0.5)

[0234] ESI-HRMS:[M+Na] + 604.3663 (Calculation: For C 28 H 55 NO 11 Na is 604.3673)

[0235] 1 H NMR (600MHz, pyridine-d5): δ8.25(t,1H,J=5.3Hz,NH),5.78(d,1H,J=3.9Hz,H-1'),5.25(dd,1H,J=2.0Hz,J=5.3H z,H-3),5.13(d,1H,J=1.8Hz,H-2),4.77(t,1H,J=5.0Hz,H-4),4.73–4.69(m,2H,H-5,H-5'),4.59(t,1H,J= 9.2Hz,H-3'),4.53(dd,1H,J=1.9Hz,J=11.5Hz,H-6'a),4.38(dd,1H,J=4.7Hz,J=11.3Hz,H-6a),4.34–4.29 (m,2H,H-6b,H-6'b),4.18(dd,1H,J=3.9Hz,J=9.5Hz,H-2'),4.14(t,1H,J=9.5Hz,H-4'),3.52–3.40(m,2H,C H 2-NH), 1.53(p, 2H, J = 7.2 Hz, C H 2-CH2-NH), 1.29–1.16 (m, 26H, CH2 alkyl chain), 0.87 (t, 3H, J=6.6Hz, CH3)

[0236] 13C NMR (151 MHz, pyridine-d5): δ 173.8 (C-1), 103.3 (C-1'), 85.3 (C-4), 75.8 (C-3'), 75.5 (C-5"), 74.7 (C-5), 74.3 (C-2'), 74.2 (C-2), 74.0 (C-3), 72.3 (C-4'), 64.6 (C-6), 63.0 (C-6'), 39.8 ( C H2-NH), 32.5–23.3 (CH2 alkyl chain), 14.6 (CH3).

[0237] N-octadecyl-D-maltobiosylamide (Mal18)

[0238]

[0239] Yield: 87%%

[0240] Appearance: white solid

[0241] Molecular formula: C 30 H 59 NO 11

[0242] MM:609.80g.mol -1

[0243] Rf:0.71(EtOAc / MeOH / H2O:7 / 2 / 1).

[0244] [α] D 20 :+70.8(MeOH,c=0.5)

[0245] ESI-HRMS:[M+Na] + 632.3980 (Calculation: For C 30 H 59 NO 11 Na is 632.3986)

[0246] 1H NMR (600MHz, pyridine-d5): δ8.23(t,1H,J=5.5Hz,NH),5.77(d,1H,J=4.0Hz,H-1'),5.26(dd,1H,J=2.2Hz,J=5.6H z,H-3),5.13(d,1H,J=2.1Hz,H-2),4.77(t,1H,J=4.9Hz,H-4),4.74–4.69(m,2H,H-5,H-5'),4.60(t,1H,J= 9.2Hz,H-3'),4.53(dd,1H,J=2.2Hz,J=11.6Hz,H-6'a),4.39(dd,1H,J=4.8Hz,J=11.3Hz,H-6a),4.35–4.30 (m,2H,H-6b,H-6'b),4.18(dd,1H,J=4.0Hz,J=9.5Hz,H-2'),4.15(t,1H,J=9.5Hz,H-4'),3.52–3.41(m,2H,C H 2-NH),1.56–1.51(m,2H,C H 2-CH2-NH), 1.29–1.17 (m, 30H, CH2 alkyl chain), 0.87 (t, 3H, J=6.8Hz, CH3)

[0247] 13 C NMR (151 MHz, pyridine-d5): δ 173.8 (C-1), 103.3 (C-1'), 85.4 (C-4), 75.8 (C-3'), 75.5 (C-5'), 74.7 (C-5), 74.3 (C-2'), 74.2 (C-2), 74.0 (C-3), 72.3 (C-4'), 64.6 (C-6), 63.0 (C-6'), 39.8 ( C H2-NH), 32.5–23.3 (CH2 alkyl chain), 14.6 (CH3).

[0248] N-N-nonadecanyl-D-maltobiose amide (Mal19)

[0249]

[0250] Yield: 69%%

[0251] Appearance: white solid

[0252] Molecular formula: C 31 H 61 NO 11

[0253] MM:623.82g.mol -1

[0254] 1 H NMR (400MHz, pyridine-d5): δ8.22(t,1H,J=5.5Hz,NH),5.78(d,1H,J=4.0Hz,H-1'),5.25(dd,1H,J=2.2Hz,J=5.6H z,H-3),5.13(d,1H,J=2.1Hz,H-2),4.77(t,1H,J=4.9Hz,H-4),4.74–4.67(m,2H,H-5,H-5'),4.60(t,1H,J= 9.2Hz,H-3'),4.55(dd,1H,J=2.2Hz,J=11.6Hz,H-6'a),4.40(dd,1H,J=4.8Hz,J=11.3Hz,H-6a),4.37–4.28 (m,2H,H-6b,H-6'b),4.20(dd,1H,J=4.0Hz,J=9.5Hz,H-2'),4.15(t,1H,J=9.5Hz,H-4'),3.55–3.40(m,2H,C H 2-NH), 1.58–1.51(m,2H,C H 2-CH2-NH), 1.35–1.14 (m, 30H, CH2 alkyl chain), 0.88 (t, 3H, J=6.8Hz, CH3)

[0255] 13 C NMR (101 MHz, pyridine-d5): δ 173.9 (C-1), 103.4 (C-1'), 85.5 (C-4), 75.9 (C-3'), 75.6 (C-5'), 74.8 (C-5), 74.4 (C-2'), 74.3 (C-2), 74.1 (C-3), 72.4 (C-4'), 64.7 (C-6), 63.1 (C-6'), 39.9 ( C H2-NH), 32.6–23.1 (CH2 alkyl chain), 14.5 (CH3).

[0256] N-Eicosyl-D-maltobiose amide (Mal20)

[0257]

[0258] Yield: 38%%

[0259] Appearance: white solid

[0260] Molecular formula: C 32 H 63 NO 11

[0261] MM:637.84g.mol-1

[0262] 1 H NMR (400MHz, pyridine-d5): δ8.25(t,1H,J=5.5Hz,NH),5.78(d,1H,J=4.0Hz,H-1'),5.25(dd,1H,J=2.2Hz,J=5.6H z,H-3),5.13(d,1H,J=2.1Hz,H-2),4.79(t,1H,J=4.9Hz,H-4),4.76–4.68(m,2H,H-5,H-5'),4.61(t,1H,J= 9.2Hz,H-3'),4.56(dd,1H,J=2.2Hz,J=11.6Hz,H-6'a),4.38(dd,1H,J=4.8Hz,J=11.3Hz,H-6a),4.44–4.27 (m,2H,H-6b,H-6'b),4.19(dd,1H,J=4.0Hz,J=9.5Hz,H-2'),4.15(t,1H,J=9.5Hz,H-4'),3.55–3.40(m,2H,C H 2-NH),1.59–1.50(m,2H,C H 2-CH2-NH), 1.37–1.11 (m, 30H, CH2 alkyl chain), 0.88 (t, 3H, J=6.8Hz, CH3)

[0263] 13 C NMR (101 MHz, pyridine-d5): δ 173.9 (C-1), 103.4 (C-1'), 85.4 (C-4), 75.9 (C-3'), 75.6 (C-5'), 74.8 (C-5), 74.4 (C-2'), 74.3 (C-2), 74.1 (C-3), 72.4 (C-4'), 64.7 (C-6), 63.1 (C-6'), 39.9 ( C H2-NH), 32.4–23.4 (CH2 alkyl chain), 14.7 (CH3).

[0264] N-Tetradecyl-D-cellobiosamide (Cell14)

[0265]

[0266] Yield: 74%

[0267] Appearance: white solid

[0268] Molecular formula: C 26 H 51 NO 11

[0269] MM:553.68g.mol -1

[0270] 1 H NMR (400MHz, pyridine-d5): δ8.31(t,1H,J=5.9Hz,NH),5.35(t,1H,J=3.2Hz,H-3),5.29(d,1H ,J=2.9Hz,H-2),5.27(d,1H,J=7.9Hz,H-1'),4.83–4.79(m,2H,H-4,H-5),4.53–4.47(m ,3H,H-6a,H-6b,H-6a'),4.23(dd,1H,J=6.7Hz,J=11.8Hz,H-6b'),4.19(t,1H,J=8.9Hz ,H-3'),4.06(t,J=8.7Hz,2H,H-2',H-4'),4.01–3.96(m,1H,H-5'),3.53–3.37(m,2H,C H 2-NH),1.56–1.50(m,2H,C H 2-CH2-NH), 1.28–1.09 (m, 22H, CH2 alkyl chain), 0.88 (t, 3H, J=6.8Hz, CH3)

[0271] 13 C NMR (101 MHz, pyridine-d5): δ 174.8 (C-1), 106.5 (C-1'), 84.3 (C-4), 79.2 (C-5'), 78.9 (C-3'), 76.0 (C-2'), 73.9 (C-5), 73.4 (C-2), 73.3 (C-3), 72.2 (C-4'), 65.2 (C-6), 63.4 (C-6'), 40.0 ( C H2-NH), 32.6–23.4 (CH2 alkyl chain), 14.6 (CH3).

[0272] N-hexadecyl-D-cellobiosamide (Cell16)

[0273]

[0274] Yield: 92%

[0275] Appearance: white solid

[0276] Molecular formula: C 28 H 55 NO 11

[0277] MM:581.74g.mol -1

[0278] Rf: 0.72 (EtOAc / MeOH / H2O: 7 / 2 / 1)

[0279] [α] D 20 :+13.8°(MeOH,c=0.5)

[0280] ESI-HRMS:[M+H] + 582.3861 (Calculation: For C 28 H 55 NO 11 is 582.3853)

[0281] 1 H NMR (600MHz, pyridine-d5): δ8.30(t,1H,J=5.9Hz,NH),5.34(t,1H,J=3.2Hz,H-3),5.27(d,1H ,J=2.9Hz,H-2),5.26(d,1H,J=7.9Hz,H-1'),4.83–4.79(m,2H,H-4,H-5),4.53–4.47(m ,3H,H-6a,H-6b,H-6a'),4.22(dd,1H,J=6.7Hz,J=11.8Hz,H-6b'),4.19(t,1H,J=8.9Hz ,H-3'),4.04(t,J=8.7Hz,2H,H-2',H-4'),3.99–3.94(m,1H,H-5'),3.49–3.38(m,2H,C H 2-NH), 1.55–1.48 (m, 2H, C H 2-CH2-NH), 1.27–1.15 (m, 26H, CH2 alkyl chain), 0.87 (t, 3H, J=6.8Hz, CH3)

[0282] 13 C NMR (151 MHz, pyridine-d5): δ 174.7 (C-1), 106.4 (C-1'), 84.2 (C-4), 79.1 (C-5'), 78.8 (C-3'), 75.9 (C-2'), 73.8 (C-5), 73.3 (C-2), 73.2 (C-3), 72.1 (C-4'), 65.1 (C-6), 63.3 (C-6'), 39.9 ( C H2-NH), 32.5–23.3 (CH2 alkyl chain), 14.6 (CH3).

[0283] N-octadecyl-D-cellobiosamide (Cell18)

[0284]

[0285] Yield: 97%

[0286] Appearance: white solid

[0287] Molecular formula: C 30 H 59 NO 11

[0288] MM:609.41 g.mol -1

[0289] Rf: 0.75 (EtOAc / MeOH / H2O: 7 / 2 / 1)

[0290] [α] D 20 :+14.8°(MeOH,c=0.5)

[0291] ESI-HRMS:[M+H] + 610.4175 (Calculation: For C 30 H 60 NO 11 is 610.4166)

[0292] 1 H NMR (400MHz, pyridine-d5): δ8.31 (t, J = 5.7Hz, 1H, NH), 5.34 (br s,1H,H-3),5.30–5.23(m,2H,H-2,H-1'),4.84–4.78(m,2H,H-4,H-5),4.57–4.45(m,3H,H-6a,H-6b,H-6a'),4.23(dd,1H,J=6.4H z,J=11.8Hz,H-6b'),4.19(t,1H,J=8.8Hz,H-3'),4.04(t,J=8.3Hz,2H,H-2',H-4'),3.99–3.95(m,1H,H-5'),3.52–3.37(m,2H,C H 2-NH), 1.53 (p, J = 6.9 Hz, 2H, C H 2-CH2-NH), 1.38–1.11 (m, 30H alkyl chain), 0.88 (t, J=6.8 Hz, 3H, CH3).

[0293] 13C NMR (101 MHz, pyridine-d5): δ 174.6 (C-1), 106.3 (C-1'), 84.1 (C-4), 79.1 (C-5'), 78.8 (C-3'), 75.9 (C-2'), 73.8 (C-5), 73.3 (C-2), 73.2 (C-3), 72.1 (C-4'), 65.0 (C-6), 63.3 (C-6'), 39.8 ( C H2-NH), 32.5–23.3 (CH2 alkyl chain), 14.6 (CH3).

[0294] N-Tetradecyl-D-lactobiosylamide (Lac14)

[0295]

[0296] Yield: 76%%

[0297] Appearance: white solid

[0298] Molecular formula: C 26 H 51 NO 11

[0299] MM:553.68g.mol -1

[0300] 1 H NMR (600MHz, pyridine-d5): δ8.18(t,1H,J=5.8Hz,NH),5.34(t,1H,J=3.0Hz,H-3),5.26(d,1H,J=2.4Hz,H-2 ),5.22(d,1H,J=7.7Hz,H-1'),4.81(dd,1H,J=4.1Hz,J=6.9Hz,H-4),4.78–4.72(m,1H,H-5),4.56–4. 45(m,4H,H-2',H-6'a,H-6a,H-6b),4.43(d,1H,J=2.9Hz,H-4'),4.29(dd,1H,J=4.6Hz,J=11.3Hz,H-6 'b),4.14(dd,1H,J=3.2Hz,J=9.4Hz,H-3'),4.08(dd,1H,J=5.4Hz,J=6.4Hz,H-5'),3.52–3.38(m,2H,C H 2-NH), 1.58–1.47(m,2H,C H 2-CH2-NH), 1.32–1.14 (m, 22H, CH2 alkyl chain), 0.88 (t, 3H, J=6.8Hz, CH3)

[0301] 13 C NMR (151 MHz, pyridine-d5): δ 174.3 (C-1), 107.0 (C-1'), 84.8 (C-4), 77.9 (C-5'), 75.7 (C-3'), 74.2 (C-2), 73.8 (C-5), 73.5 (C-2'), 73.0 (C-3), 70.7 (C-4'), 64.9 (C-6), 63.0 (C-6'), 39.9 ( C H2-NH), 32.6–23.4 (CH2 alkyl chain), 14.7 (CH3).

[0302] N-hexadecyl-D-lactobiosylamide (Lac16)

[0303]

[0304] Yield: 69%%

[0305] Appearance: white solid

[0306] Molecular formula: C 28 H 55 NO 11

[0307] MM:581.74g.mol -1

[0308] Rf: 0.69 (EtOAc / MeOH / H2O: 7 / 2 / 1)

[0309] [α] D 20 :+22.0°(MeOH,c=0.05)

[0310] ESI-HRMS:[M+H] + 582.3852 (Calculation: For C 28 H 55 NO 11 is 582.3853)

[0311] 1H NMR (600MHz, pyridine-d5): δ8.19(t,1H,J=5.8Hz,NH),5.32(t,1H,J=3.0Hz,H-3),5.24(d,1H,J=2.4Hz,H-2 ),5.21(d,1H,J=7.7Hz,H-1'),4.80(dd,1H,J=4.1Hz,J=6.9Hz,H-4),4.74–4.71(m,1H,H-5),4.51–4. 45(m,4H,H-2',H-6'a,H-6a,H-6b),4.42(d,1H,J=2.9Hz,H-4'),4.27(dd,1H,J=4.6Hz,J=11.3Hz,H-6 'b),4.12(dd,1H,J=3.2Hz,J=9.4Hz,H-3'),4.06(dd,1H,J=5.4Hz,J=6.4Hz,H-5'),3.48–3.38(m,2H,C H 2-NH), 1.55–1.48 (m, 2H, C H 2-CH2-NH), 1.27–1.16 (m, 26H, CH2 alkyl chain), 0.87 (t, 3H, J=6.8Hz, CH3)

[0312] 13 C NMR (151 MHz, pyridine-d5): δ 174.2 (C-1), 106.9 (C-1'), 84.6 (C-4), 77.8 (C-5'), 75.6 (C-3'), 74.1 (C-2), 73.7 (C-5), 73.4 (C-2'), 72.9 (C-3), 70.6 (C-4'), 64.8 (C-6), 62.9 (C-6'), 39.8 ( C H2-NH), 32.5–23.3 (CH2 alkyl chain), 14.6 (CH3).

[0313] N-octadecyl-D-lactobiose amide (Lac18)

[0314]

[0315] Yield: 86%

[0316] Appearance: white solid

[0317] Molecular formula: C 30 H 59 NO 11

[0318] MM:609.80g.mol -1

[0319] Rf: 0.71 (EtOAc / MeOH / H2O: 7 / 2 / 1)

[0320] [α] D 20 :+136.0°(MeOH,c=0.025)

[0321] ESI-HRMS:[M+H] + 610.4166 (Calculation: For C 30 H 60 NO 11 is 610.4166)

[0322] 1 H NMR (600MHz, pyridine-d5): δ8.19(t,1H,J=5.9Hz,NH),5.32(br s,1H,H-3),5.24(d,1H,J=2.5Hz,H-2),5.21(d,1H,J=7.8Hz,H-1'),4.80(dd,1H,J=4 .0Hz,J=7.0Hz,H-4),4.74–4.72(m,1H,H-5),4.52–4.45(m,4H,H-2',H-6'a,H-6a,H-6 b),4.42(d,1H,J=3.1Hz,H-4'),4.27(dd,1H,J=4.4Hz,J=11.2Hz,H-6'b),4.12(dd,1H ,J=3.3Hz,J=9.5Hz,H-3'),4.06(dd,1H,J=5.0Hz,J=7.0Hz,H-5'),3.48–3.38(m,2H,C H 2-NH), 1.55–1.48 (m, 2H, C H 2-CH2-NH), 1.29–1.16 (m, 30H, CH2 alkyl chain), 0.87 (t, 3H, J=6.9Hz, CH3)

[0323] 13 C NMR (151 MHz, pyridine-d5): δ 174.2 (C-1), 106.9 (C-1'), 84.7 (C-4), 77.9 (C-5'), 75.6 (C-3'), 74.1 (C-2), 73.7 (C-5), 73.4 (C-2'), 72.9 (C-3), 70.6 (C-4'), 64.8 (C-6), 62.9 (C-6'), 39.8 ( C H2-NH), 32.5 (CH2 alkyl chain), 30.6–23.3 (CH2 alkyl chain), 14.6 (CH3)

[0324] N-Tetradecyl-Melibioseamide (Mel14)

[0325]

[0326] Yield: 60%

[0327] Appearance: white solid

[0328] Molecular formula: C 26 H 51 NO 11

[0329] MM:553.35g.mol -1

[0330] 1 H NMR (400 MHz, pyridine-d5): δ 8.39 (t, J = 5.9 Hz, NH), 5.46 (d, J = 3.7 Hz, 1H, H-1'), 5.21 (t, J = 3.2 Hz, 1H, H-3), 5.04 (d, J = 3.3 Hz, 1H, H-2), 4.78–4.70 (m, 2H, H-4', H-4), 4.68 (dd, J = 9.9, 3.8 Hz, 1H, H-2'), 4.63–4.56 (m, 3H, H-6 a,b, H-5'), 4.51 (dd, J = 9.9, 3.1 Hz, 1H, H-3'), 4.42 (d, J = 5.9 Hz, 2H, H-6'a,b), 4.38–4.32 (m, 1H, H-5), 3.56–3.37 (m, 2H, CH2-N), 1.63–1.49 (m, 2H, CH2-CH2-N), 1.33–1.12 (m, 22H, CH2 alkyl chain), 0.88 (t, J = 6.7 Hz, 3H, CH3).

[0331] 13 C NMR (101 MHz, pyridine-d5): δ 174.5 (C-1), 101.60 (C-1'), 75.3 (C-2), 75.1 (C-4), 73.2 (C-5'), 72.7 (C-3), 72.1 (C-3'), 71.4 (C-5, C-6), 71.4 (C-4'), 71.1 (C-2'), 63.0 (C-6'), 40.0 (CH2-N), 33.0-23.4 (CH2 alkyl chain), 14.7 (CH3).

[0332] N-hexadecyl-melbiose amide (Mel16)

[0333]

[0334] Yield: 44%

[0335] Appearance: white solid

[0336] Molecular formula: C 28 H 55 NO 11

[0337] MM:581.38g.mol -1

[0338] 1 H NMR (400 MHz, pyridine-d5): δ8.39 (t, J = 5.9 Hz, NH), 5.45 (d, J = 3.7 Hz, 1H, H-1'), 5.21 (t, J = 3.2 Hz, 1H, H-3), 5.04 (d, J = 3.3 Hz, 1H, H-2), 4.78–4.70 (m, 2H, H-4', H-4), 4.67 (dd, J = 9.9, 3.8 Hz, 1H, H-2'), 4.62–4.55 (m, 3H, H-6 a,b, H-5'), 4.51 (dd, J = 9.9, 3.1 Hz, 1H, H-3'), 4.41 (d, J = 5.9 Hz, 2H, H-6'a,b), 4.38–4.30 (m, 1H, H-5), 3.54–3.40 (m, 2H, CH2-N), 1.62–1.51 (m, 2H, CH2-CH2-N), 1.34–1.12 (m, 26H, CH2 alkyl chain), 0.88 (t, J = 6.7 Hz, 3H, CH3).

[0339] 13 C NMR (101 MHz, pyridine-d5): δ 174.5 (C-1), 101.6 (C-1'), 75.3 (C-2), 75.1 (C-4), 73.2 (C-5'), 72.7 (C-3), 72.1 (C-3'), 71.4 (C-5, C-6), 71.4 (C-4'), 71.1 (C-2'), 63.0 (C-6'), 40.0 (CH2-N), 33.0-23.4 (CH2 alkyl chain), 14.8 (CH3).

[0340] N-octadecyl-melbiose amide (Mel18)

[0341]

[0342] Yield: 38%

[0343] Appearance: white solid

[0344] Molecular formula: C 30 H 59 NO11

[0345] MM:609.41 g.mol -1

[0346] 1 H NMR (400 MHz, pyridine-d5): δ 8.39 (t, J = 5.9 Hz, NH), 5.46 (d, J = 3.7 Hz, 1H, H-1'), 5.21 (t, J = 3.2 Hz, 1H, H-3), 5.04 (d, J = 3.3 Hz, 1H, H-2), 4.78–4.70 (m, 2H, H-4', H-4), 4.68 (dd, J = 9.9, 3.8 Hz, 1H, H-2'), 4.62–4.56 (m, 3H, H-6 a,b, H-5'), 4.51 (dd, J = 9.9, 3.1 Hz, 1H, H-3'), 4.42 (d, J = 5.9 Hz, 2H, H-6'a,b), 4.38–4.31 (m, 1H, H-5), 3.54–3.40 (m, 2H, CH2-N), 1.62–1.51 (m, 2H, CH2-CH2-N), 1.34–1.12 (m, 30H, CH2 alkyl chain), 0.88 (t, J = 6.7 Hz, 3H, CH3).

[0347] 13 C NMR (101 MHz, pyridine-d5): δ 174.5 (C-1), 101.6 (C-1'), 75.3 (C-2), 75.1 (C-4), 73.2 (C-5'), 72.7 (C-3), 72.1 (C-3'), 71.4 (C-5, C-6), 71.4 (C-4'), 71.1 (C-2'), 63.0 (C-6'), 40.0 (CH2-N), 33.0-23.4 (CH2 alkyl chain), 14.8 (CH3).

[0348] II-2.c). General procedure for the sulfation of N-alkyl-glucamides

[0349] To 1 g of N-alkyl-glucamide in 50 mL of anhydrous pyridine in a two-necked flask, 2 x 1.1 equivalents of 50% SO3 / pyridine complex active for glucosamide and 3 x 1.1 equivalents of 50% SO3 / pyridine complex active for maltotriosamide were added. The progress of the reaction was monitored by reversed phase thin layer chromatography (C18 stationary phase, eluent methanol / water 6 / 4). After about one hour of reaction, 1.5 equivalents of another 50% SO3 / active pyridine were added to complete the reaction. The reaction was left under stirring overnight and then treated with a saturated sodium bicarbonate solution at a pH of about 9 and then evaporated to dryness. The disulfated compound (N-alkyl-glucamide) or the trisulfated N-alkyl maltotriosamide was the majority of the product obtained in the reaction medium, with a few compounds formed being incompletely sulfated at the primary position or containing additional sulfate groups. The crude reaction was then purified by reverse phase flash chromatography using a C1880g Reveleris column. The mobile phase was a water / methanol mixture at a flow rate of 40 mL / min, with a gradient starting from 40% methanol and rising to 80% methanol in 10 min. The purified monosulfated, disulfated (very predominantly) and trisulfated N-alkylglubiosylamide or trisulfated N-alkylmaltotriosylamide fractions were then evaporated to remove methanol and then freeze-dried.

[0350] Disodium N-tetradecyl-6,6'-di-O-sulfo-D-maltobiosylamide (Mal14diS)

[0351]

[0352] Yield: 61%

[0353] Appearance: white solid

[0354] Molecular formula: C 26 H 49 NNa2O 17 S2

[0355] MM:757.22g.mol -1

[0356] Rf: 0.47 (CH3CN / H2O: 3 / 7) TLC-C18

[0357] ESI-HRMS:[M+Na] + 780.2133 (Calculation: For C 26 H 49 NNa3O 17 S2 is 780.2135)

[0358] 1H NMR (600MHz, D2O): δ5.22 (d, J=3.9Hz, 1H, H-1'), 4.41–4.10 (m, 8H, H-6'a, H-6'b, H-2, H-5, H-6a, H-6b, H-3, H-5'), 4.00 (dd, J=5.7, 3.8Hz ,1H,H-4),3.81(t,J=9.5Hz,1H,H-3'),3.65(dd,J=9.9,3.8Hz,1H,H-2'),3.57(t,J=9.6Hz,1H,H-4'),3.34–3.18(m,2H,CH2-N),1.57(br s,2H,CH2-CH2-N),1.33(br s,22H,CH2 alkyl chain),0.92(t,J=6.5Hz,3H,CH3)

[0359] 13 C NMR (151 MHz, D2O): δ 173.4 (C-1), 100.5 (C-1'), 82.0 (C-4), 72.7 (C-3'), 71.8 (C-2), 71.7 (C-3), 71.5 (C-2'), 70.5 (C-5'), 69.8 (C-5), 68.9 (C-6), 68.8 (C-4'), 66.7 (C-6'), 39.4 (CH2-N), 32.0–22.6 (CH2 alkyl chain), 13.9 (CH3).

[0360] Disodium N-hexadecyl-6,6'-di-O-sulfo-D-maltobiosylamide (Mal16diS)

[0361]

[0362] Yield: 55%

[0363] Appearance: white solid

[0364] Molecular formula: C 28 H 53 NNa2O 17 S2

[0365] MM:785.82g.mol -1

[0366] Rf: 0.52 (CH3CN / H2O: 6 / 4) TLC-C18

[0367] [α] D 20 :+53.6°(H2O,c=0.5)

[0368] ESI-HRMS:[M+Na] +808.2463 (Calculation: For C 28 H 53 NNa3O 17 S2 is 808.2448)

[0369] 1 H NMR (400MHz, D2O): δ5.21 (d, J=3.9Hz, 1H, H-1'), 4.40–4.09 (m, 8H, H-6'a, H-6'b, H-2, H-5, H-6a, H-6b, H-3, H-5'), 3.99 (dd, J=5.7, 3.8Hz ,1H,H-4),3.81(t,J=9.5Hz,1H,H-3'),3.64(dd,J=9.9,3.8Hz,1H,H-2'),3.56(t,J=9.6Hz,1H,H-4'),3.33–3.17(m,2H,CH2-N),1.56(br s,2H,CH2-CH2-N),1.33(br s,26H,CH2 alkyl chain),0.92(t,J=6.5Hz,3H,CH3)

[0370] 13 C NMR (101 MHz, D2O): δ 173.4 (C-1), 100.5 (C-1'), 82.0 (C-4), 72.8 (C-3'), 71.8 (C-2), 71.7 (C-3), 71.5 (C-2'), 70.5 (C-5'), 69.8 (C-5), 68.9 (C-6), 68.8 (C-4'), 66.7 (C-6'), 39.4 (CH2-N), 32.0–22.6 (CH2 alkyl chain), 13.9 (CH3).

[0371] Sodium N-hexadecyl-6 or 6'-O-sulfo-D-maltobiosylamide (Mal16monoS)

[0372] The monosulfated fraction of Mal16 was obtained from crude Mal16diS purified on a flash chromatography column. This is a mixture of N-hexadecylmaltobiosamide sulfated at position 6 and its homologue sulfated at position 6'.

[0373]

[0374] Yield: 40%

[0375] Appearance: white solid

[0376] Molecular formula: C 28 H 54 NNaO 14 S

[0377] MM:683.78g.mol -1

[0378] Trisodium N-hexadecyl-tri-O-sulfo-D-maltobiosylamide (Mal16triS)

[0379] The trisulfated fraction of Mal16 was obtained from crude Mal16diS purified on a flash chromatography column. It is a mixture of several N-hexadecylmaltobiosylamide compounds disulfated at the 6 and 6' positions and containing a third sulfate group at one of the minor positions.

[0380]

[0381] Yield: 6%

[0382] Appearance: white solid

[0383] Molecular formula: C 28 H 52 NNa3O 20 S3

[0384] MM:887.86g.mol -1

[0385] Disodium N-octadecyl-6,6'-di-O-sulfo-D-maltobiosylamide (Mal18diS)

[0386]

[0387] Yield: 49%

[0388] Appearance: white solid

[0389] Molecular formula: C 30 H 57 NNa2O 17 S2

[0390] MM:813.88 g.mol -1

[0391] Rf: 0.44 (CH3CN / H2O: 6 / 4) TLC-C18

[0392] [α] D 20 :+39.2°(H2O,c=0.125)

[0393] ESI-HRMS:[M+Na] + 836.2776 (Calculation: For C 30 H 57 NNa3O 17 S2 is 836.2761)

[0394] 1 H NMR (400MHz, D2O): δ5.23(d,J=3.8Hz,1H,H-1'),4.45–4.08(m,8H,H-6'a,H-6'b,H-2,H-5,H-6a,H-6b,H-3,H-5'),4.01(t,J=4.8Hz,1 H,H-4),3.83(t,J=9.5Hz,1H,H-3'),3.67(dd,J=9.9,3.5Hz,1H,H-2'),3.58(t,J=9.5Hz,1H,H-4'),3.41–3.10(m,2H,CH2-N),1.58(br s,2H,CH2-CH2-N),1.33(br s, 30H, CH2 alkyl chain), 0.93 (t, J = 6.5 Hz, 3H, CH3).

[0395] 13 C NMR (D2O, 101 MHz): δ173.4 (C-1), 100.5 (C-1'), 82.0 (C-4), 72.8 (C-3'), 71.8 (C-2), 71.6 (C-3), 71.5 (C-2'), 70.5 (C-5'), 69.8 (C-5), 68.9 (C-6), 68.9 (C-4'), 66.7 (C-6'), 39.5 (CH2-N), 32.1–22.7 (CH2 alkyl chain), 13.9 (CH3).

[0396] Sodium N-octadecyl-6 or 6'-O-sulfo-D-maltobiosylamide (Mal18monoS)

[0397] The monosulfated fraction of Mal18 was obtained from crude Mal18diS purified on a flash chromatography column. This is a mixture of N-octadecylmaltobiosamide sulfated at position 6 and its homologue sulfated at position 6'.

[0398]

[0399] Yield: 37%

[0400] Appearance: white solid

[0401] Molecular formula: C 30 H 58 NNaO 14 S

[0402] MM:711.84 g.mol -1

[0403] Trisodium N-octadecyl-tri-O-sulfo-D-maltobiosylamide (Mal18triS)

[0404] The trisulfated fraction of Mal18 was obtained from crude Mal18diS purified on a flash chromatography column. It is a mixture of several N-octadecylmaltobiosamide compounds disulfated at the 6 and 6' positions and containing a third sulfate group at one of the secondary positions.

[0405]

[0406] Yield: 5%

[0407] Appearance: white solid

[0408] Molecular formula: C 30 H 56 NNa3O 20 S3

[0409] MM:915.91g.mol -1

[0410] Disodium N-nonadecyl-6,6'-di-O-sulfo-D-maltobiosylamide (Mal19diS)

[0411]

[0412] Yield: 47%

[0413] Appearance: white solid

[0414] Molecular formula: C 31 H 59 NNa2O 17 S2

[0415] MM:827.90g.mol -1

[0416] 1 H NMR (400MHz, D2O): δ5.22(d,J=3.8Hz,1H,H-1'),4.42–4.09(m,8H,H-6'a,H-6'b,H-2,H-5,H-6a,H-6b,H-3,H-5'),4.00(t,J=4.8Hz,1 H,H-4),3.82(t,J=9.5Hz,1H,H-3'),3.65(dd,J=9.9,3.5Hz,1H,H-2'),3.57(t,J=9.5Hz,1H,H-4'),3.35–3.15(m,2H,CH2-N),1.57(br s,2H,CH2-CH2-N),1.33(br s, 32H, CH2 alkyl chain), 0.91 (t, J = 6.5 Hz, 3H, CH3).

[0417] 13 C NMR (D2O, 101 MHz): δ173.4 (C-1), 100.5 (C-1'), 82.0 (C-4), 72.7 (C-3'), 71.9 (C-2), 71.5 (C-3), 71.5 (C-2'), 70.5 (C-5'), 69.8 (C-5), 68.9 (C-6), 68.9 (C-4'), 66.7 (C-6'), 39.5 (CH2-N), 32.1–22.7 (CH2 alkyl chain), 13.9 (CH3).

[0418] Disodium N-eicosyl-6,6'-di-O-sulfo-D-maltobiosylamide (Mal20diS)

[0419]

[0420] Yield: 32%

[0421] Appearance: white solid

[0422] Molecular formula: C 32 H 61 NNa2O 17 S2

[0423] MM:841.32g.mol -1

[0424] 1 H NMR (400MHz, D2O): δ5.23(d,J=3.8Hz,1H,H-1'),4.42–4.08(m,8H,H-6'a,H-6'b,H-2,H-5,H-6a,H-6b,H-3,H-5'),4.01(t,J=4.8Hz,1 H,H-4),3.82(t,J=9.5Hz,1H,H-3'),3.66(dd,J=9.9,3.5Hz,1H,H-2'),3.57(t,J=9.5Hz,1H,H-4'),3.36–3.14(m,2H,CH2-N),1.57(br s,2H,CH2-CH2-N),1.33(br s, 34H, CH2 alkyl chain), 0.91 (t, J = 6.5 Hz, 3H, CH3).

[0425] 13C NMR (D2O, 101 MHz): δ173.4 (C-1), 100.5 (C-1'), 82.0 (C-4), 72.8 (C-3'), 71.8 (C-2), 71.6 (C-3), 71.5 (C-2'), 70.5 (C-5'), 69.8 (C-5), 68.9 (C-6), 68.9 (C-4'), 66.7 (C-6'), 39.5 (CH2-N), 32.1–22.7 (CH2 alkyl chain), 13.9 (CH3).

[0426] N-hexadecyl-per-O-sulfo-D-maltobiosylamide disodium salt (Mal16perS)

[0427]

[0428] N-hexadecyl-D-maltobiose amide (Mal16) compound (200mg, 0.34mmol) and 20 equivalents of 97% SO3 / active pyridine were introduced into a 20mL zirconium oxide bowl containing 80 zirconium oxide balls with a diameter of 5mm and then introduced into a P7PL Fritsch planetary grinder. The mixture was ground at 400rpm for 48 cycles of 5min each. Then 30 equivalents of NaHCO3 (578mg, 6.88mmol) were introduced into the bowl and the mixture was ground again for 6 cycles of 5min each. The crude reaction was then dissolved in milliQ water and dialyzed using a 1000kD cutoff membrane (3x 500mL). After freeze drying, a white solid was obtained and analyzed by high-resolution mass spectrometry. Mal16perS consists of a mixture (524mg) of tri-, tetra-, penta-, hexa-, hepta- and octa-sulfated N-hexadecyl-D-maltobiose amide.

[0429] Disodium N-Tetradecyl-6,6'-di-O-sulfo-D-cellobiosamide (Cell14diS)

[0430]

[0431] Yield: 69%

[0432] Appearance: white solid

[0433] Molecular formula: C 26 H 49 NNa2O 17 S2

[0434] MM:757.22g.mol -1

[0435] 1H NMR(400MHz,D2O): δ4.69(d,J=7.9Hz,1H,H-1'),4.44(bs,1H,H-2),4.40–4.33(m,4H,H-6'a ,H-6a,H-6b,H-3),4.33–4.10(m,2H,H-6'b,H-5),4.06(dd,J=7.7,3.2Hz,1H,H-4'),3.79–3 .71(m,1H,H-5),3.60–3.48(m,2H,H-3',H-4'),3.40(t,J=8.4Hz,1H,H-2'),3.32–3.20(m,2H,CH2-N),1.61-1.51(m,2H,CH2-CH2-N),1.33(s,22H,CH2 alkyl chain),0.91(t,J=6.4Hz,3H,CH3).

[0436] 13 C NMR (101 MHz, D2O): δ 173.5 (C-1), 102.6 (C-1'), 80.5 (C-4), 75.3 (C-3'), 73.7 (C-5'), 73.2 (C-2'), 72.9 (C-2), 69.5 (C-3), 69.3 (C-4'), 68.9 (C-5, C-6), 66.8 (C-6'), 39.3 (CH2-N), 31.7–22.4 (CH2 alkyl chain), 13.8 (CH3).

[0437] Disodium N-hexadecyl-6,6'-di-O-sulfo-D-cellobiosamide (Cell16diS)

[0438]

[0439] Yield: 59%

[0440] Appearance: white solid

[0441] Molecular formula: C 28 H 53 NNa2O 17 S2

[0442] MM:785.82g.mol -1

[0443] Rf:0.6(H2O / CH3CN:65 / 35)TLC-C18

[0444] ESI-HRMS:[M+Na] + 808.2472 (Calculation: For C 28 H 53 NNa3O 17S2 is 808.2448)

[0445] 1 H NMR(400MHz,D2O): δ4.69(d,J=7.9Hz,1H,H-1'),4.45(bs,1H,H-2),4.40–4.27(m,4H,H-6'a ,H-6a,H-6b,H-3),4.24–4.13(m,2H,H-6'b,H-5),4.07(dd,J=7.7,3.2Hz,1H,H-4'),3.77–3 .73 (m, 1H, H-5), 3.58–3.48 (m, 2H, H-3', H-4'), 3.44 (t, J = 8.4 Hz, 1H, H-2'), 3.32–3.18 (m, 2H, CH2-N), 1.58–1.54 (m, 2H, CH2-CH2-N), 1.33 (s, 26H, CH2 alkyl chain), 0.93 (t, J = 6.4 Hz, 3H, CH3).

[0446] 13 C NMR (D2O, 101 MHz): δ173.5 (C-1), 102.6 (C-1'), 80.5 (C-4), 75.3 (C-3'), 73.9 (C-5'), 73.2 (C-2'), 72.9 (C-2), 69.7 (C-3), 69.5 (C-4'), 68.9 (C-5, C-6), 67.0 (C-6'), 39.4 (CH2-N), 32.0–22.7 (CH2 alkyl chain), 14.0 (CH3).

[0447] Disodium N-octadecyl-6,6'-di-O-sulfo-D-cellobiosamide (Cell18diS)

[0448]

[0449] Yield: 66%

[0450] Appearance: white solid

[0451] Molecular formula: C 30 H 57 NNa2O 17 S2

[0452] MM:813.88 g.mol -1

[0453] Rf: 0.22 (CH3CN / H2O: 2 / 8) TLC-C18

[0454] ESI-HRMS:[M+Na] +836.2803 (Calculation: For C 30 H 57 NNa3O 17 S2 is 836.2761)

[0455] 1 H NMR(400MHz,D2O): δ4.69(d,J=7.9Hz,1H,H-1'),4.45(bs,1H,H-2'),4.41–4.26(m,4H,H-6' a,H-6a,H-6b,H-3),4.24–4.13(m,2H,H-6'b,H-5),4.07(dd,J=7.7,3.2Hz,1H,H-4'),3.78– 3.72 (m, 1H, H-5), 3.60–3.48 (m, 2H, H-3', H-4'), 3.41 (t, J = 8.4 Hz, 1H, H-2'), 3.32–3.18 (m, 2H, CH2-N), 1.63–1.52 (m, 2H, CH2-CH2-N), 1.34 (s, 30H, CH2 alkyl chain), 0.93 (t, J = 6.4 Hz, 3H, CH3).

[0456] 13 C NMR (101 MHz, D2O): δ 173.4 (C-1), 102.6 (C-1'), 80.5 (C-4), 75.3 (C-3'), 73.9 (C-5'), 73.2 (C-2'), 72.8 (C-2), 69.7 (C-3), 69.5 (C-4'), 68.9 (C-5, C-6), 67.0 (C-6'), 39.4 (CH2-N), 32.0–22.7 (CH2 alkyl chain), 13.9 (CH3).

[0457] Disodium N-Tetradecyl-6,6'-di-O-sulfo-lactobiosamide (Lac14diS)

[0458]

[0459] Yield: 72%

[0460] Appearance: white solid

[0461] Molecular formula: C 26 H 49 NNa2O 17 S2

[0462] MM:757.22g.mol -1

[0463] Rf: 0.23 (H2O / CH3CN: 7 / 3) TLC-C18

[0464] ESI-HRMS:[M+Na] + 780.2146 (Calculation: For C 26 H 49 NNa3O 17 S2 is 780.2135)

[0465] 1 H NMR (400MHz, D2O): δ4.63(d,J=7.7Hz,1H,H-1'),4.45(bs,1H,H-2),4.42–4.26(m,3H,H-6a,H-6b,H-3 ),4.24(d,J=5.9Hz,2H,H-6'a,H-6'b),4.20–4.13(m,1H,H-5),4.08(dd,J=8.0,2.9Hz,1H,H-4),4.09 –3.94 (m, 2H, H-4’, H-5), 3.72 (dd, J = 10.0, 3.3 Hz, 1H, H-3’), 3.62 (dd, J = 9.9, 7.6 Hz, 1H, H-2’), 3.36–3.16 (m, 2H, CH2-N), 1.63–1.50 (m, 2H, CH2-CH2-N), 1.32 (s, 22H, CH2 alkyl chain), 0.92 (t, J = 6.4 Hz, 3H, CH3).

[0466] 13 C NMR (101 MHz, D2O): δ173.5 (C-1), 103.1 (C-1'), 80.4 (C-4), 72.9 (C-2), 72.8 (C-4'), 72.4 (C-3'), 70.9 (C-2'), 69.7 (C-3), 69.1 (C-5, C-6), 68.3 (C-5'), 66.7 (C-6'), 39.4 (CH2-N), 32.0–22.6 (CH2 alkyl chain), 13.9 (CH3).

[0467] Disodium N-hexadecyl-6,6'-di-O-sulfo-lactobiosamide (Lac16diS)

[0468]

[0469] Yield: 72%

[0470] Appearance: white solid

[0471] Molecular formula: C 28 H 53 NNa2O 17 S2

[0472] MM:785.82g.mol -1

[0473] Rf: 0.23 (H2O / CH3CN: 7 / 3) TLC-C18

[0474] ESI-HRMS:[M+Na] + 808.2473 (Calculation: For C 28 H 53 NNa3O 17 S2 is 808.2448)

[0475] 1 H NMR (400MHz, D2O): δ4.64(d,J=7.7Hz,1H,H-1'),4.46(bs,1H,H-2),4.43–4.28(m,3H,H-6a,H-6b,H-3 ),4.24(d,J=5.9Hz,2H,H-6'a,H-6'b),4.20–4.13(m,1H,H-5),4.08(dd,J=8.0,2.9Hz,1H,H-4),4.05 –3.99 (m, 2H, H-4’, H-5), 3.72 (dd, J = 10.0, 3.3 Hz, 1H, H-3’), 3.63 (dd, J = 9.9, 7.6 Hz, 1H, H-2’), 3.36–3.16 (m, 2H, CH2-N), 1.64–1.52 (m, 2H, CH2-CH2-N), 1.33 (s, 26H, CH2 alkyl chain), 0.92 (t, J = 6.4 Hz, 3H, CH3).

[0476] 13 C NMR (101 MHz, D2O): δ 173.5 (C-1), 103.1 (C-1'), 80.4 (C-4), 72.9 (C-2), 72.8 (C-4'), 72.4 (C-3'), 70.9 (C-2'), 69.7 (C-3), 69.0 (C-5, C-6), 68.3 (C-5'), 66.7 (C-6'), 39.4 (CH2-N), 32.0–22.7 (CH2 alkyl chain), 13.9 (CH3).

[0477] Disodium N-octadecyl-6,6'-di-O-sulfo-lactobiosamide (Lac18diS)

[0478]

[0479] Yield: 64%

[0480] Appearance: white solid

[0481] Molecular formula: C 30 H 57 NNa2O 17 S2

[0482] MM:813.88 g.mol -1

[0483] Rf: 0.36 (H2O / CH3CN: 7 / 3) TLC-C18

[0484] ESI-HRMS:[M+Na] + 836.2798 (Calculation: For C 30 H 57 NNa3O 17 S2 is 836.2761)

[0485] 1 H NMR (D2O, 400MHz): δ4.65 (d, J=7.6Hz, 1H, H-1'), 4.47 (bs, 1H, H-2), 4.43–4.28 (m, 3H ), 4.24 (d, J = 5.7 Hz, 2H, H-6'a, H-6'b), 4.18 (d, J = 7.1 Hz, 1H, H-5), 4.15–4.06 (m, 1H, H-4), 4.07–4.00 (m, 2H, H-4', H-5), 3.73 (dd, J = 10.1, 3.0 Hz, 1H, H-3'), 3.65 (dd, J = 9.8, 7.6 Hz, 1H, H-2'), 3.36–3.16 (m, 2H, CH2-N), 1.65–1.49 (m, 2H, CH2-CH2-N), 1.34 (s, 30H, CH2 alkyl chain), 0.93 (t, J = 6.4 Hz, 3H, CH3).

[0486] 13 C NMR (D2O, 101 MHz): δ173.5 (C-1), 103.1 (C-1'), 80.3 (C-4), 72.9 (C-2), 72.8 (C-4'), 72.4 (C-3'), 70.9 (C-2'), 69.7 (C-3), 68.9 (C-5, C-6), 68.3 (C-5'), 66.7 (C-6'), 39.5 (CH2-N), 32.0–22.7 (CH2 alkyl chain), 13.9 (CH3).

[0487] Sodium N-tetradecyl-6'-O-sulfo-melbiose amide (Mel14monoS)

[0488]

[0489] Yield: 48%

[0490] Appearance: white solid

[0491] Molecular formula: C 26 H 50 NNaO 14 S

[0492] MM:655.28g.mol -1

[0493] Rf: 0.32 (H2O / CH3CN: 7 / 3) TLC-C18

[0494] ESI-HRMS:[M+Na] + 678.2750 (Calculation: For C 26 H 50 NNa3O 14 S is 678.2747)

[0495] 1 H NMR(400MHz,D2O): δ5.03(d,J=3.7Hz,1H,H-1'),4.35(bs,1H,H-2),4.30–4.14(m,4 H,H-6'a,H-6'b,H-5',H-3),4.08(d,J=3.2Hz,1H,H-4'),4.01–3.90(m,4H,H-3',H- 5, H-4, H-2'), 3.75 (dd, J = 22, 7.2 Hz, 1H, H-6a, H-6b), 3.38–3.12 (m, 2H, CH2-N), 1.66–1.50 (m, 2H, CH2-CH2-N), 1.47–1.21 (s, 22H, CH2 alkyl chain), 0.92 (t, J = 6.4 Hz, 3H, CH3).

[0496] 13 C NMR (101 MHz, D2O): δ 173.7 (C-1), 98.4 (C-1'), 73.6 (C-2), 72.3 (C-4), 70.1 (C-3), 69.6 (C-5), 69.3 (C-3'), 69.2 (C-4'), 68.6 (C-6, C-5'), 68.4 (C-2'), 67.4 (C-6'), 39.4 (CH2-N), 32.1–22.7 (CH2 alkyl chain), 13.9 (CH3).

[0497] Sodium N-hexadecyl-6'-O-sulfo-melbiose amide (Mel16monoS)

[0498]

[0499] Yield: 53%

[0500] Appearance: white solid

[0501] Molecular formula: C 28 H 54 NNaO 14 S

[0502] MM:683.32g.mol -1

[0503] Rf: 0.22 (H2O / CH3CN: 7 / 3) TLC-C18

[0504] ESI-HRMS:[M+Na] + 706.3082 (Calculation: For C 28 H 54 NNa3O 14 S is 706.3060)

[0505] 1 H NMR(400MHz,D2O): δ5.03(d,J=3.7Hz,1H,H-1'),4.35(bs,1H,H-2),4.29–4.13(m,4 H,H-6'a,H-6'b,H-5',H-3),4.08(d,J=3.2Hz,1H,H-4'),4.01–3.90(m,4H,H-3',H- 5,H-4,H-2'), 3.75(dd, J=22,7.2Hz,1H,H-6a,H-6b),3.37–3.14(m,2H,CH2-N),1.63–1.52(m,2H,CH2-CH2-N),1.46-1.18(s,26H,CH2 alkyl chain),0.91(t, J=6.4Hz,3H,CH3).

[0506] 13 C NMR (101 MHz, D2O): δ 173.7 (C-1), 98.4 (C-1'), 73.6 (C-2), 72.3 (C-4), 70.1 (C-3), 69.6 (C-5), 69.3 (C-3'), 69.1 (C-4'), 68.7 (C-6), 68.6 (C-5'), 68.4 (C-2'), 67.4 (C-6'), 39.4 (CH2-N), 32.1–22.7 (CH2 alkyl chain), 13.9 (CH3).

[0507] Sodium N-octadecyl-6'-O-sulfo-melbiose amide (Mel18monoS)

[0508]

[0509] Yield: 38%

[0510] Appearance: white solid

[0511] Molecular formula: C 30 H 58 NNaO 14 S

[0512] MM:711.35g.mol -1

[0513] Rf: 0.16 (H2O / CH3CN: 7 / 3) TLC-C18

[0514] ESI-HRMS:[M] - 688.3569 (Calculation: For C 30 H 58 NO 14 S is 688.3578)

[0515] 1 H NMR(400MHz,D2O): δ5.03(d,J=3.7Hz,1H,H-1'),4.35(bs,1H,H-2),4.28–4.14(m,4 H,H-6'a,H-6'b,H-5',H-3),4.08(d,J=3.2Hz,1H,H-4'),4.01–3.81(m,4H,H-3',H- 5, H-4, H-2'), 3.75 (dd, J = 22, 7.2 Hz, 1H, H-6a, H-6b), 3.37–3.14 (m, 2H, CH2-N), 1.63–1.52 (m, 2H, CH2-CH2-N), 1.46–1.18 (s, 30H, CH2 alkyl chain), 0.91 (t, J = 6.4 Hz, 3H, CH3).

[0516] 13 C NMR (101 MHz, D2O): δ 173.7 (C-1), 98.5 (C-1'), 73.7 (C-2), 72.3 (C-4), 70.1 (C-3), 69.6 (C-5), 69.3 (C-3'), 69.1 (C-4'), 68.7 (C-6), 68.6 (C-5'), 68.4 (C-2'), 67.4 (C-6'), 39.4 (CH2-N), 32.1–22.7 (CH2 alkyl chain), 13.9 (CH3).

[0517] II-3. Synthesis of oxidized glucobiosylamide

[0518] According to the following reaction diagram (schematic Figure 2 ) was used to synthesize oxidized glucosylamide.

[0519]

[0520] Hint Figure 2 :Synthetic pathway of oxidized glucobiosylamide

[0521] The synthesis of oxidized glucobiose amides involves three steps, the first two of which are identical to the synthesis of sulfated derivatives: oxidation at the anomeric position and one-pot esterification-aminolysis to graft the lipid chain through an amide bond.

[0522] Step 3 : The primary hydroxyl group of the disaccharide was oxidized by TEMPO / BAIB and NaHCO3 system in a CH3CN / H2O mixture (48h) (Lu, H. et al., Molecules 2016, 21(10), 1301 / 1-1301 / 15). NMR and HRMS analysis showed that the loss of carbon-C6 (by decarboxylation) had occurred, similar to that described in the literature, with a pyruvate motif (Coggins, AJ et al., Nature Chemistry 2017, 9(4), 310-317; Lee Y et al., Chem Commun 2014, 50).

[0523] For the Mal16diBu-perS compound, two additional steps are required: esterification-aminolysis (step 4) followed by persulfation (step 5) (schematic diagram Figure 2 (middle Bu = butyl).

[0524] N-hexadecyl-D-glucuronyl-(α-1,4)-D-xylulose amide (Mal16diOx)

[0525]

[0526] The N-hexadecyl-maltobiose amide derivative (0.60mmol, 350mg) was dissolved in a mixture of acetonitrile (4mL) and mQH2O (4mL). The mixture was stirred at 0°C and TEMPO (1.20mmol, 187mg) was added, followed by BAIB (6.02mmol, 1.94g) and NaHCO3 (3.01mmol, 253mg). The mixture was then stirred at room temperature for 72h. Ethanol (10mL) was added and the reaction medium was diluted with EtOAc (100mL) and mQ H2O (100mL). The aqueous phase was separated and extracted with EtOAc (2×100mL) and then freeze-dried. The crude reaction was then purified by reverse phase chromatography. The elution gradient was H2O / MeCN: 100 / 0 to 0 / 100 in 20min. After evaporation and freeze-drying, the Mal16diOx compound was obtained in the form of a white powder with a yield of 8% (31mg).

[0527] M:623.65g.mol -1

[0528] Formula: C 27 H 47 NNa2O 12

[0529] Rf:0.51(H2O / MeCN:5 / 5)

[0530] HRMS:602.3150 (for C 27 H 49 NO 12 Na was found to be 602.3152)

[0531] 1 H NMR (D2O, 400 MHz): 5.14 (m, 1H, H Glc1’ ),4.20(m,3H,H Glc2 ,H Glc3 and H Glc5’ ),4.10(d,1H,J=6.0Hz,H Glc4 ),3.93(t,1H,J=9.4Hz,H Glc3’ ),3.65(d,1H,J=9,6Hz,H Glc2’ ),3.50(t,1H,J=9.5Hz,H Glc4’ ),3.22(m,2H,C H 2-NH),1.55(m,2H,C H 2-CH2-NH), 1.32 (m, 26H, CH2 alkyl chain), 0.90 (t, 3H, J=6.2Hz, CH3 alkyl chain)

[0532] 13 C NMR (D2O, 100MHz): 177.22 (C Glc5 ),176.93(C Glc6’ ),173.68(C Glc1 ),100.66(C Glc1’ ),83.33(C Glc4 ),72.84(C Glc2 or C Glc3 ),72.55(C Glc2 or C Glc3 ),72.44(C Glc3’ ),72.07(C Glc4’ ),71.59(C Glc5’ ),71.29(C Glc2’ ),39.38( C H2-NH), 32.09 (CH2 alkyl chain), 30.16-29.11 (CH2 alkyl chain), 27.14 (CH2 alkyl chain), 22.71 (CH2 alkyl chain), 13.86 (CH3 alkyl chain).

[0533] N-octadecyl-D-glucuronyl-(α-1,4)-D-xylulose amide (Mal18diOx)

[0534]

[0535] The N-hexadecyl-maltobiose amide derivative (0.82mmol, 500mg) was dissolved in a mixture of acetonitrile (5mL) and mQH2O (5mL). The mixture was stirred at 0°C and TEMPO (1.64mmol, 256mg) was added, followed by BAIB (8.20mmol, 2.64g) and NaHCO3 (4.10mmol, 344mg). The mixture was then stirred at room temperature for 48h. Ethanol (5mL) was added and the reaction medium was diluted with EtOAc (200mL) and mQ H2O (200mL). The aqueous phase was separated and extracted with EtOAc (2×200mL) and then freeze-dried. The crude reactant was then purified by reverse phase chromatography. The elution gradient was H2O / MeCN: 100 / 0 to 0 / 100 in 20min. After evaporation and freeze-drying, the Mal18diOx compound was obtained in the form of a white powder with a yield of 17% (90mg).

[0536] M:651.70g.mol -1

[0537] Formula: C 29 H 51 NNa2O 12

[0538] Rf:0.48(H2O / MeCN:5 / 5)

[0539] HRMS:630.3466(for C 29 H 53 NO 12 Na was found to be 630.3465)

[0540] 1 H NMR (D2O, 400 MHz): 5.14 (m, 1H, H Glc1’ ),4.20(m,3H,H Glc2 ,H Glc3 and H Glc5’ ),4.10(d,1H,J=6.0Hz,H Glc4 ),3.94(t,1H,J=8.7Hz,H Glc3’ ),3.66(d,1H,J=9,6Hz,H Glc2’ ),3.50(t,1H,J=9.5Hz,H Glc4’ ),3.21(m,2H,C H 2-NH),1.54(m,2H,C H 2-CH2-NH), 1.32 (m, 30H, CH2 alkyl chain), 0.88 (t, 3H, J=6.2Hz, CH3 alkyl chain)

[0541] 13 C NMR (D2O, 100MHz): 177.31 (C Glc5 ),176.94(C Glc6’ ),173.68(C Glc1 ),100.71(C Glc1’ ),82.38(C Glc4 ),72.80(C Glc2 or C Glc3 ),72.55(C Glc2 or C Glc3 or C Glc3’ ),72.04(C Glc4’ ),71.74(C Glc5’ ),71.23(C Glc2’ ),39.43( C H2-NH), 32.24 (CH2 alkyl chain), 30.68-29.19 (CH2 alkyl chain), 27.35 (CH2 alkyl chain), 22.82 (CH2 alkyl chain), 13.84 (CH3 alkyl chain).

[0542] N-hexadecyl-(D-glucuronyl-(α-1,4)-D-xylulose amide) dibutylamide (Mal16diBu)

[0543]

[0544] N-hexadecyl-D-glucuronyl-(α-1,4)-D-xylulose amide (0.127 mmol, 79 mg) and H2SO4 / SiO2 22 wt% (0.305 mmol, 136 mg) were added to a zirconia bowl containing 80 zirconia balls of 5 mL diameter. MeOH (0.15 mL) was added. The media was milled in a planetary ball mill (P7PL) at 500 rpm for 8 cycles of 5 min each with a 2 min break in reverse mode. The methyl ester obtained was directly used in the subsequent reaction under the same milling conditions. 99.5% butylamine (0.381 mmol, 38 μL) was added to the bowl followed by MeOH (0.15 mL). The media was milled in a planetary ball mill (P7PL) at 500 rpm for 8 cycles of 5 min each with a 2 min break in reverse mode. The crude reactant was dissolved in MeOH, filtered to remove H2SO4 / SiO2 and evaporated. The residue was purified by automated flash chromatography on a 15 g SiO2 column. The elution gradient was: EtOAc / MeOH: 100 / 0 to 80 / 20 in 30 min. After evaporation and freeze drying, the Ma16diBu compound was obtained in the form of a white powder in 40% yield (35 mg).

[0545] M:689.93g.mol -1

[0546] Formula: C 35 H 67 N3O 10

[0547] Rf: 0.57 (EtOAc / MeOH: 9 / 1)

[0548] 1 H NMR (600 MHz, pyridine-d5,): 8.34 (m, 3H, NH), 5.70 (d, 1H, J = 3.2 Hz, H Glc1’ ),5.22(d,1H,J=5.1Hz,H Glc2 ),5.03(m,8H,H Glc3 ,H Glc4 ,Hglc5' Glc5’ and OH), 4.59(t,1H,J=9.1Hz,H Glc3’ ),4.27(t,1H,J=9.4Hz,H Glc4’),4.13(dd,1H,J=9,5Hz,J=3.4Hz,H Glc2’ ),3.45(m,5H,C H 2-NH),3.27(s x ,1H,J=6.5Hz,C H 2-NH),1.53(m,6H,C H 2-CH2-NH), 1.24 (m, 30H, CH2 hexadecylamine and butylamine chain), 0.86 (t, 3H, J = 6.1Hz, CH3 hexadecylamine and butylamine chain), 0.79 (m, 6H, CH3 hexadecylamine and butylamine chain)

[0549] 13 C NMR (150MHz, pyridine-d5,): 173.53 (C Glc1 ),171.75(C Glc5 or C Glc6’ ),171.71(C Glc5 or C Glc6’ ),103.19(C Glc1’ ),84.74(C Glc4 ),74.61(C Glc3’ ),74.16(C Glc4’ ),74.10(C Glc2 ),73.91(C Glc3 or C Glc5’ ),73.22(C Glc2’ ),39.85( C H2-NH butyl chain), 39.68( C H2-NH butyl chain), 39.47( C H2-NH hexadecyl chain), 32.09 (CH2 hexadecyl chain), 32.38 (CH2 butyl chain), 32.36 (CH2 butyl chain), 30.58-29.98 (CH2 hexadecyl chain), 27.66 (CH2 hexadecyl chain), 23.31 (CH2 hexadecyl chain), 20.79 (CH2 butyl chain), 20.69 (CH2 butyl chain), 14.65 (CH3 hexadecyl chain), 14.26 (CH3 butyl chain), 14.24 (CH3 butyl chain)

[0550] N-hexadecyl-(D-glucuronyl-(α-1,4)-D-xylulose amide) dibutylamide persulfate (Mal16diBu-perS)

[0551]

[0552] The Mal16diBu-perS derivative was obtained according to the same procedure as that for obtaining Mal16perS. Mal16diBu compound (35 mg, 0.051 mmol) and 16 equivalents of 97% SO3 / active pyridine were introduced into a 20 mL zirconium oxide bowl containing 80 zirconium oxide balls with a diameter of 5 mm and then introduced into a P7PL Fritsch planetary grinder. The mixture was ground at 400 rpm for 48 cycles of 5 min each. Then 16 equivalents of NaHCO3 (69 mg, 0.81 mmol) were introduced into the bowl and the mixture was ground again for 6 cycles of 5 minutes each. The crude reactant was then dissolved in milliQ water and dialyzed using a 1000 kD cut-off membrane (3 x 500 mL). Mal16diBu-perS (52 mg) was obtained in the form of a mixture of N-hexadecyl-(D-glucuronyl-(α-1,4)-D-xylulose amide) dibutyramide tri-, tetra- and pentasulfate salts.

[0553] III. Biological Data

[0554] 1) In vitro test of abnormal phosphorylation of Tau protein

[0555] Tau protein phosphorylation is the most common post-translational modification that regulates Tau activity and function. The longest Tau isoform (4R2N, 441 amino acids) was used, which contains 85 potential phosphorylation sites. In vitro phosphorylation of Tau protein is achieved by induction ( Figure 5 ), and on the other hand, it is based on the competition process between LG2A molecules and heparin, which is usually used to induce abnormal Tau phosphorylation in vitro ( Figure 3 , Figure 4 , Figure 6 , Figure 7 , Figure 8 , Fig. 9 and Fig.10 ).

[0556] For abnormal Tau phosphorylation test, GSK3β, a kinase centrally involved in the process in the brain of patients with Alzheimer's disease (AD), was used. Tau phosphorylation occurring through GSK3β at AD characteristic sites can be analyzed by Western blotting technique using specific antibodies that recognize abnormal phosphorylation sites in the brain or cerebrospinal fluid of AD subjects (such as AT270 antibody that recognizes threonine 181 (Thr181), PHF1 antibody that recognizes serine 396 and 404 (Ser396 / Ser404), and AT8 antibody that recognizes Ser199 / Ser202 / Thr205 sites).

[0557] Experimental protocol

[0558] The composition of the reaction medium is as follows:

[0559] By induction : Tau protein (40 μg / mL) (Millipore) was phosphorylated by 4 ng / mL of GSK3β enzyme (Promega) in the presence of 48 μM ATP (Sigma-Aldrich) and protease inhibitors (Sigma-Aldrich, 1 / 100) in a buffer (40 mM Tris [pH 7.5], 20 mM MgCl2, 0.1 mg / mL BSA and 0.1 mM DTT). 12 μg / mL of LG2A molecules were added and their effects were compared with those observed by adding the same concentration of heparin.

[0560] Through competition : Tau protein (40 μg / mL) was phosphorylated by 4 ng / mL of GSK3β enzyme (Promega) in the above buffer in the presence of 48 μM ATP (Sigma-Aldrich) and protease inhibitors (Sigma-Aldrich, 1 / 100). The ability of LG2A molecules (60 μg / mL) to compete with heparin (12 μg / mL; Sigma-Aldrich) was evaluated. Therefore, if the signal in the presence of this molecule is less than the signal obtained with heparin alone, this molecule is defined as a "protector" of abnormal Tau phosphorylation.

[0561] In both systems (induction or competition), Tau protein was incubated with stirring at 37°C in the presence of the above different elements. The reaction kinetics were monitored by taking 8 μL samples at 1.5h, 3h and 6h of incubation. Loading buffer (Euromedex) and β-mercaptoethanol (Sigma-Aldrich) were added to each sample. The samples were then stored at -20°C until analysis by Western blot.

[0562] After heating at 95°C for 5 minutes to denature the samples, the samples were mixed with molecular weight markers (Precision Plus Protein TM Dual Color Standard; BIO-RAD) were simultaneously deposited on a 10% acrylamide gel placed in an electrophoresis tank containing migration buffer (0.25 M Tris; 1.6 M glycine; 20% SDS; pH 8.6).

[0563] Controls used for this phosphorylation experiment and subsequent western blots were:

[0564] - "Native Tau" protein, i.e. non-phosphorylated Tau protein.

[0565] -Tau protein phosphorylated by GSK3b alone in the absence of heparin.

[0566] - Tau protein phosphorylated in the presence of heparin, denoted as "Tau+Heparin".

[0567] - An "external standard" corresponding to Tau protein phosphorylated for 3h in the presence of heparin. This standard is performed in the presence of the LG2A compound, in an experiment independent of the phosphorylation experiment. It ensures that the western blot was performed correctly.

[0568] Migration was performed at a constant 80 V until the protein reached the separation gel, which was visualized by the migration front of bromophenol blue contained in the loading buffer, and then at a constant 120 V until the migration front reached the other end of the gel.

[0569] At the end of the migration, semi-dry transfer was performed on a polyvinylidene fluoride (PVDF) membrane using the "Trans-blot Turbo RTA Transfer Kit, PVDF" (Bio-Rad). The PVDF membrane was activated in methanol (VWR) beforehand and then placed in the transfer buffer provided in the kit.

[0570] The transfer was performed at 25 V for 10 minutes.

[0571] After the protein transfer to the PVDF membrane was completed, a saturation step was performed in PBS containing 3% skim milk powder (Merck Millipore) and 0.1% Tween 20 (VWR) at room temperature with stirring for 1 h.

[0572] The membrane was then incubated overnight at +4°C with agitation in a solution of PBS, 0.1% Tween and 1% milk containing primary antibodies specific for Tau phosphorylation sites (AT270, ThermoScientific or S199-202, Millipore).

[0573] After incubation of the PVDF membrane in the primary antibody of choice, the membrane was washed three times in PBS and 0.1% Tween for 5 min each with agitation and incubated in a solution containing diluted secondary antibody (Jackson Immuno-Research) in 1X PBS, 0.1% Tween and 1% milk for 1 h at room temperature with agitation.

[0574] After washing three times for 5 minutes each with PBS and 0.1% Tween and then once with PBS, the membrane was revealed using the "ImmobilonForte Western HRP Substrate" kit (Merck Millipore) and the signal was recorded by a LI-COR instrument (Odyssey).

[0575] result

[0576] In the absence of heparin (highly sulfated HS), no Tau phosphorylation was observed at sites characteristic of AD (Sepulveda-Diaz et al., 2015) ( Figure 2 However, in the presence of heparin (highly sulfated HS), all Tau sites became phosphorylated (p-Tau), reproducing the abnormal hyperphosphorylation process that occurs in cells before tauopathies are established.

[0577] Using in vitro tests, it has been shown that starting from 1.5h and until 6h of reaction, the synthetic disulfated C16 maltobiose amide (Mal16diS) enters into complete competition with heparin (Hep), preventing heparin from inducing Tau phosphorylation at the two abnormal Tau phosphorylation sites characteristic of Alzheimer's disease analyzed (AT270 and Ser 199 / 202). Thus, after 3h of in vitro reaction, the presence of disulfated C16 maltobiose amide (Mal16diS) inhibits the abnormal Tau phosphorylation (P-Tau) revealed by antibodies characteristic of Alzheimer's disease (AT270 and Ser199 / 202). The results are shown in Figure 3 middle.

[0578] Similarly, after 1.5, 3, and 6 h of reaction, the synthesized disulfated C18 maltodiosylamide (Mal18diS) entered into complete competition with heparin (Hep) on the Tau AD site (AT270). Therefore, after 3 h of reaction, the presence of disulfated C18 maltodiosylamide (Mal18diS) inhibited the abnormal phosphorylation of Tau (P-Tau) revealed by Alzheimer's disease characteristic antibodies (AT270 and pSer199 / 202) ( Figure 4 ).

[0579] However, when the ability of maltodiamide compounds, whose hydrocarbon chain (R1) contained 14 to 20 carbons (Mal14diS to Mal20diS), to induce abnormal phosphorylation of Tau by themselves (i.e. in the absence of heparin) was investigated, it was shown that the longer the hydrocarbon chain of the compound, the more it induced p-Tau ( Figure 5 ).

[0580] Therefore, for the same ability to protect Tau from aberrant phosphorylation, it is preferred to select compounds with the shortest lipid chain length.

[0581] Effect of disaccharides

[0582] To investigate the effect of disaccharide properties, analogous disulfide cellobiose amide and lactobiose amide derivatives containing 14 to 18 carbons in the hydrocarbon chain were synthesized.

[0583] In terms of the ability to enter full competition with heparin at 1.5 to 6 h after Tau phosphorylation by GSK3b, Figure 6 For reaction 3h, only the cellobiose amide and lactobiose amide compounds containing 16-carbon and 18-carbon hydrocarbon chains ("Cell16diS", "Cell18diS", "Lac16diS" and "Lac18diS", respectively) showed similar results to the disulfide maltobiose amide containing 16-carbon hydrocarbon chains ("Mal16diS") and 18-carbon hydrocarbon chains ("Mal18diS").

[0584] Melbisulfonamide derivatives containing 14, 16, or 18 carbon hydrocarbon chains ("Mel14monoS", "Mel16monoS", and "Mel18monoS", respectively) do not compete with heparin for aberrant Tau phosphorylation ( Figure 6 ). Thus, with these latter derivatives, it appears that the single anionic charge or the conformation of the disaccharide is unfavorable to compete with heparin and prevent aberrant Tau phosphorylation.

[0585] Effects of sulfation

[0586] Oxidized compounds similar to maltobiose amide containing 16 or 18 carbon hydrocarbon chains were synthesized to assess the necessity of sulfation of the sugar moiety of the compounds for their anti-p-Tau activity. It was observed that the oxidized compound containing a 16 carbon hydrocarbon chain ("Mal16diOx") was not as effective as the disulfated maltobiose amide compound (Mal16diS) of the same chain length in preventing Tau phosphorylation ( Figure 7 Unlike the disulfide analog containing an 18-carbon hydrocarbon chain ("Mal18diS"), the oxidized compound containing an 18-carbon hydrocarbon chain ("Mal18diOx") does not compete with heparin.

[0587] Therefore, sulfation of the disaccharide is crucial to compete with heparin (the prototype of the hypersulfated HS present in Alzheimer's disease) and prevent aberrant Tau phosphorylation.

[0588] To elucidate the importance of disaccharide sulfation, maltobiose amide derivatives containing 16 or 18 monosulfated carbons ("mal16monoS" and "mal18monoS", respectively) or trisulfated carbons ("mal16triS" and "mal18triS", respectively) in the hydrocarbon chain were synthesized.

[0589] Compounds "Mal16monoS", "Mal16triS", "mal18monoS" and "mal18triS" showed (i) a slight loss of the ability to protect Tau from heparin-induced phosphorylation when maltobiose amide lost its sulfate group ("Mal16monoS" and "Mal18 monoS"), and (ii) this ability to protect Tau remained unchanged when the compounds gained sulfate groups ("Mal16triS" and "Mal18triS"). Figure 8 ).

[0590] Furthermore, when the 16-carbon maltobiose amide compound was persulfated (Mal16perS), it retained the ability to protect Tau from heparin-induced aberrant phosphorylation, as did its disulfated homologue of the same lipid chain length ( Fig. 9 ).

[0591] 2) Induce Tau protein aggregation

[0592] The ability of the 16-carbon disulfated maltodisylamide compound "Mal16diS" to induce Tau protein aggregation, another step in the development of neurofibrillary tangles, was evaluated.

[0593] Therefore, the ability of this molecule to induce or inhibit Tau aggregation in vitro was assessed in the test ( Fig.10 ), which was described in Sui et al., 2015, where Tau aggregation was monitored by incorporation of Thioflavin T (ThT).

[0594] Experimental protocol

[0595] Aggregation assays were performed using custom synthesized Tau protein (4R2N isoform, 441 amino acids) from supplier Tebu-bio (manufactured on April 17, 2019; initial concentration: 2.47 mg / mL) in black 96-well plates with a final volume of 100 μL and under different conditions:

[0596] A solution of Tau protein alone (0.71 mg / mL) in buffer (40 mM Tris [pH 7.45], 200 mM NaCl, 2 mM EDTA, and 1 mM DTT).

[0597] A solution of Tau protein (0.71 mg / mL) in the above buffer in the presence of 0.35 mg / mL (mass ratio of 2 / 1) or 0.175 mg / mL (mass ratio of 4 / 1) heparin.

[0598] A solution of Tau protein (0.71 mg / mL) in the above buffer in the presence of 0.175 mg / mL (mass ratio 4 / 1) Mal16diS.

[0599] 100 μL of 50 μM ThT (Sigma-Aldrich) was immediately added to each well, and the plate was then incubated with agitation at 37° C. The formation of Tau aggregates was monitored by monitoring the incorporation of thioflavin resulting in its fluorescence emission, and was read at λExc 450 nm / λEm 510 nm at 0, 24, 40, 48, and 71 h using an Infinite M1000 spectrofluorometer (Tecan).

[0600] result

[0601] Until 72 h of reaction, the tested Mal16diS compounds induced Tau protein aggregation more weakly than heparin ( Fig.10 ).

[0602] 3) In-cell test of abnormal Tau phosphorylation

[0603] Prior to testing Tau phosphorylation in cells, cytotoxicity studies were performed on the neuroblastoma cell line SH-SY5Y.

[0604] a) Cytotoxicity studies

[0605] The molecules that showed the best potential in the in vitro Tau phosphorylation test: disulfated maltobiose amides with 16 and 18 carbons were tested for cytotoxicity. To assess the toxicity level of these molecules based on their concentration in the cellular environment, an MTT test (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was performed upstream of the intracellular phosphorylation test. Fig.11 and Fig.12 ).

[0606] Experimental protocol

[0607] SH-SY5Y (ATCC-CRL-2266) were cultured in a 37°C and 5% CO2 incubator in Dulbecco's modified Eagle's medium (DMEM-GlutaMAX) containing 10% fetal bovine serum (FBS) and 1% penicillin / streptomycin. TM , Life Technologies) developed.

[0608] To this end, SH-SY5Y cells were cultured in 6-well plates at a cell density of 200,000 cells / well and differentiated for 5 days using retinoic acid (10 μM, Sigma Aldrich). On day 6, cells were exposed to LG2A molecules at different concentrations (0.1, 1, 10 or 100 μg / mL) in a final volume of 2 mL. After 24 hours, MTT (5 μg / mL; Sigma-Aldrich) was added to the cell culture medium and kept at 37 ° C for 2 hours. The culture medium was then removed and 200 μL of pure dimethyl sulfoxide (DMSO, Sigma-Aldrich) was added to each well. The entire contents of each well were transferred to a 96-well plate and the absorbance was measured at 562 nm using an Infinite M1000 fluorescence spectrometer (Tecan).

[0609] result

[0610] From the lowest dose of 0.1 μg / mL to the highest dose of 100 μg / mL, 16-disulfated maltodiose amide (Mal16diS) had no cytotoxicity to SH-SY5Y cells ( Fig.11 ).

[0611] Similarly, it has been shown that 18-carbon disulfated maltobiose amide (Mal18diS) has no cytotoxicity to SH-SY5Y cells from the lowest dose of 0.1 μg / mL to the highest dose of 100 μg / mL ( Fig.12 ).

[0612] Furthermore, the tested compounds were not found to induce an additional inflammatory state in HMC3 cells after stimulation with lipopolysaccharide (LPS) (50 ng / mL), as measured by interleukin 6, when compounds were added at doses of 0.1, 1 or 10 μg / mL, compared to the same cells receiving LPS only (data not shown).

[0613] b) In-cell assay in SH-SY5Y line

[0614] The Tau phosphorylation induction model on the SH-SY5Y cell line described in the article by the Gly-CRRET laboratory was used here (Sepulveda-Diaz et al., 2015).

[0615] Experimental protocol

[0616] In brief, SH-SY5Y cells were seeded in 6-well plates and differentiated for 5 days using retinoic acid (10 μM, Sigma Aldrich). On the 6th day, cells were placed in the presence of Mal16diS and Mal18diS molecules at different concentrations (1, 10 or 100 μg / mL) with holes that did not receive the molecules, and the final volume was 2 mL. After 24 hours, the molecules were removed, and stress inducers (H2O2, Sigma Aldrich) were added to the cell culture medium for 30 minutes. The cells were then rinsed with 1X PBS, then cracked and recovered in RIPA buffer (Thermo Fisher). Protein extracts (10 μg) from cells were then analyzed by Western blot according to the same procedure described above.

[0617] The Tau phosphorylation site studied here is the S262 site (Thermo Fisher), normalized to the expression of the GAPDH protein (Sigma Aldrich). The bands were quantified using the Odyssey software of the LI-COR device to allow the calculation of the p-Tau / GAPDH ratio under each condition. The ratio obtained for each concentration of the molecule was then expressed as a percentage of the ratio obtained for control cells (i.e., not treated with the molecule). Therefore, values ​​less than 100% correspond to the protection provided by the molecule in this Tau phosphorylation-induced cell model.

[0618] The experiments were repeated at least 4 times for each molecular dose for the "Mal16diS" and "Mal18diS" molecules, and at least twice for the "Cell16diS" and "Lac16diS" molecules. The mean and standard deviation of the replicates are shown in Figures 13 to 16 Each value obtained for each dose was compared with the control value without added molecule by means of t-test. Statistical differences with p values ​​< 0.05 and < 0.001 are indicated by "*" and "***", respectively.

[0619] result

[0620] The two lowest doses of 16-carbon disulfated maltobiose amide ("mal16diS") tested (1 and 10 μg / mL) allowed a significant (p<0.01) reduction of Tau phosphorylation in SH-SY5Y cells by 30 and 40% (P<0.01) compared to untreated cells. Fig.13 ).

[0621] In the case of 18-carbon disulfated maltobiose amide ("mal18diS"), greater reductions in Tau phosphorylation were observed with increasing compound concentrations. Using the highest dose of 100 μg / mL, up to 60% reduction in Tau phosphorylation was observed compared to untreated cells (p<0.001); the lowest dose provided nearly 30% protection from oxidative stress-induced Tau phosphorylation (p<0.001). Fig.14 ).

[0622] At the lowest dose of 1 μg / mL, 16-carbon disulfated cellobiosylamide ("cell16diS") provided approximately 34% reduction in Tau phosphorylation in SH-SY5Y cells compared to untreated cells; however, this difference was not statistically significant. The same was true for doses of 10 and 100 μg / mL of the compound, with 17 and 20% protection against Tau, respectively ( Fig.15 ).

[0623] Finally, for 16-carbon disulfated lactobiose amide ("lac16diS"), the lowest dose of 1 μg / mL provided a nearly significant (p=0.069) 25% reduction in Tau phosphorylation in SH-SY5Y cells. The 10 μg / mL dose of this compound was not tested. The highest dose of this molecule at 100 μg / mL provided 54% protection from Tau phosphorylation compared to untreated control cells (p<0.01)( Fig.16 ).

[0624] c) Intracellular assay in rTg4510 mouse cortical cells

[0625] Unlike previous cell models, cortical cells from rTg4510 mice that harbor a mutation for human Tau (P301L) were used as a primary cell model for tauopathy without effector-induced expression (Santa Cruz et al., Science, 2005).

[0626] Experimental protocol

[0627] Cortical cells were extracted from E16 stage mouse embryos expressing the P301L mutation and cultured in 6-well plates. On day 14 (moderate Tau phosphorylation) or day 18 (severe Tau phosphorylation), cells extracted from the same embryos were placed in the presence of different concentrations (0.1 or 1 μg / mL) of the Mal16diS molecule in a final volume of 2 mL for 24 h, simultaneously with wells where cells from the same embryos did not receive the molecule.

[0628] After 24 h of treatment with the molecules, the cells were washed with 1X PBS, then lysed and recovered in RIPA buffer (Thermo Fischer). Protein extracts (10 μg) from the cells were then analyzed by Western blotting according to the same procedure as above.

[0629] The Tau phosphorylation site studied here is the S262 site (Thermo Fisher), normalized to the expression of total Tau protein (K9JA, Dako). The bands were quantified using the Odyssey software of the LI-COR instrument to allow the calculation of the p-Tau / Tau ratio under each condition. The ratio obtained for each concentration of the molecule was then expressed as a percentage of the ratio obtained for cells not treated with the molecule. Therefore, values ​​less than 100% correspond to the protection provided by the molecule in this Tau phosphorylation expression cell model.

[0630] For each dose of the "Mal16diS" molecule, the experiment was repeated at least three times. The mean and standard deviation of the replicates are shown in Fig.17 and Fig.18 Each value obtained for each dose was compared with the value of cells without added molecule using t-test. Statistical differences with p values ​​< 0.01 and < 0.001 are indicated by "**" and "***", respectively.

[0631] result

[0632] When Tau phosphorylation in rTg4510 mouse cortical cells was moderate (J14), both doses of 16-carbon disulfated maltobisamide ("mal16diS") tested (0.1 and 1 μg / mL) allowed a significant reduction of this Tau phosphorylation by 48% (p<0.01) and 64% (p<0.001) ( Fig.17 , n=4).

[0633] This reduction in phosphorylation in primary cultures of cortical cells was maintained when cells exhibited more intense phosphorylation prior to treatment (J18), particularly with a 39% and 53% reduction for the 0.1 and 1 μg / mL doses of "mal16diS", respectively ( Fig.18 , n=4).

Claims

1. A compound of the following formula (I) for medical use: in: L is a -C(=O)NH-, -C(=O)O- or -C(=O)S- group; R1 is a linear or branched, saturated or unsaturated hydrocarbon chain containing 15, 16, 17 or 18 carbon atoms, optionally substituted at the terminal position with a group selected from -OH, -OR, -NH2, -NHR, -NRR', -COOH, -COOR, -CONHR, -CONRR' and -SR, wherein R and R' independently represent an alkyl group containing from one to six carbon atoms; R4 is a group of formula (IIa) or (IIb): in: R9 and R 10 independently of one another are a hydrogen atom or a sulfonic acid group in ionized form; R 12 is an alkyl radical containing from one to six carbon atoms; R 11 Is -CH2-OR5 or -CONHR 13 Group, in which: R5 is a hydrogen atom or a sulfonic acid group in ionized form; R 13 is an alkyl radical containing from one to six carbon atoms; R2, R3, R6, R7 and R8 are independently of one another a hydrogen atom or a sulfonic acid group in ionized form; and Among them, R2, R3, R5, R6, R7, R8, R9 and R 10 At least one of the groups, preferably R2, R3, R5, R6, R7, R8, R9 and R 10 At least two of the groups are sulfonic acid groups in ionized form.

2. The compound for use according to claim 1, wherein R 11 is a CH2-OR5 group, and R5 is as defined in claim 1.

3. The compound for use according to claim 1 or 2, which has the following formula (Ib): Where R1 to R3 and R5 to R 10 As claimed in claim 1 or 2.

4. The compound for use according to any one of the preceding claims, which has the following formula (Ic): Where R1 to R3 and R5 to R 10 As described in claim 1.

5. The compound for use according to claim 1, which has the following structure (Ie): Where R1 to R3 and R5 to R 10 As described in claim 1.

6. The compound for use according to claim 1, having the following structure (Ig): Where R1 to R3 and R5 to R 10 As described in claim 1.

7. The compound for use according to any one of the preceding claims, wherein R1 is a saturated linear hydrocarbon chain comprising 15, 16, 17 or 18 carbon atoms, preferably 16 and 18 carbon atoms.

8. The compound for use according to any one of the preceding claims, wherein R2, R3, R6, R7, R8 and R 10 is a hydrogen atom, and R5 and R9 are sulfonic acid groups in ionized form.

9. The compound for use according to any one of the preceding claims, which is selected from the following compounds: Where n = 15 or 17; Where n = 15 or 17; Where n = 15 or 17; Where n = 15; Where n = 15 or 17; Where n = 15 or 17; Where n=15.

10. A compound according to any one of claims 1 to 9 for use in the treatment of Tauopathy.

11. A compound as claimed in any one of claims 1 to 9 for use in the treatment of Alzheimer's disease.

12. A pharmaceutical composition comprising a compound of formula (I) as claimed in any one of claims 1 to 9 and one or more pharmaceutically acceptable excipients.

13. The pharmaceutical composition according to claim 12 for treating Tauopathy.

14. A compound having the following structure (Ic): R1 is a linear or branched, saturated or unsaturated hydrocarbon chain containing 15, 16, 17 or 18 carbon atoms, optionally substituted at the terminal position with a group selected from -OH, -OR, -NH2, -NHR, -NRR', -COOH, -COOR, -CONHR, -CONRR' and -SR, wherein R and R' independently represent an alkyl group containing from one to six carbon atoms; R5 is a hydrogen atom or a sulfonic acid group in ionized form; R9 and R 10 independently of one another are a hydrogen atom or a sulfonic acid group in ionized form; R2, R3, R6, R7 and R8 are independently of one another a hydrogen atom or a sulfonic acid group in ionized form; and Among them, R2, R3, R5, R6, R7, R8, R9 and R 10 At least one of the groups, preferably R2, R3, R5, R6, R7, R8, R9 and R 10 At least two of the groups are sulfonic acid groups in ionized form.